var title_f1_45_1744="F waves";
var content_f1_45_1744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    F waves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 542px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The F wave is visible as a low amplitude late potential following the M response. External stimulation depolarizes peripheral nerves, triggering electrical potentials that propagate both proximally and distally. With motor nerves, electrical activity moving distally results in a direct motor response, the compound muscle action potential, also known as the CMAP or the M response. Electrical activity propagating proximally activates a small percentage of motor neurons (they \"backfire\"), which then generate the F wave. The F wave latency varies depending upon the conductivity of the",
"    <span style=\"LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt\">",
"     subpopulation",
"    </span>",
"    of motor neurons activated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1744=[""].join("\n");
var outline_f1_45_1744=null;
var title_f1_45_1745="Hypopyon";
var content_f1_45_1745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hypopyon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A postoperative eye showing a hypopyon, the layering of white blood cells in the anterior chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the department of Ophthalmology and Vision Science, University of Toronto.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1745=[""].join("\n");
var outline_f1_45_1745=null;
var title_f1_45_1746="Patient information: Vaccines when you have hepatitis C (The Basics)";
var content_f1_45_1746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/46/41698\">",
"         Patient information: Hepatitis A (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/61/22483\">",
"         Patient information: Hepatitis A (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/45/31447\">",
"         Patient information: Hepatitis B (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/4/17478\">",
"         Patient information: Hepatitis C (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines when you have hepatitis C (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-when-you-have-hepatitis-c-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19918667\">",
"      <span class=\"h1\">",
"       Which vaccines do people with hepatitis C need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with hepatitis C need some of the same vaccines that all people need, plus some extra ones, too. People with hepatitis C need vaccines against:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Hepatitis A",
"        </strong>",
"        &mdash; People with hepatitis C should get 2 doses of this vaccine at some point during their adult life. But the vaccine is not needed if blood tests show that a person is already protected against hepatitis A.",
"       </li>",
"       <li>",
"        <strong>",
"         Hepatitis B",
"        </strong>",
"        &mdash; People with hepatitis C should get 3 doses of this vaccine at some point during their adult life. But the vaccine is not needed if blood tests show that a person is already protected against hepatitis B.",
"       </li>",
"       <li>",
"        <strong>",
"         Pneumonia",
"        </strong>",
"        (this is called the pneumococcal vaccine) &mdash; People with hepatitis C should get 1 to 2 doses of this vaccine between ages of 19 and 64. They should also get another dose after turning 65 if it's been more than 5 years since their last dose.",
"       </li>",
"       <li>",
"        <strong>",
"         The flu",
"        </strong>",
"        (this is called the influenza vaccine, or the &ldquo;flu shot&rdquo;) &mdash; People with hepatitis C should get 1 dose of this vaccine every year.",
"       </li>",
"       <li>",
"        <strong>",
"         Diphtheria and tetanus",
"        </strong>",
"        &mdash; Vaccines against these 2 diseases are usually together in 1 shot. People with hepatitis C should get 1 dose of these vaccines every 10 years.",
"       </li>",
"       <li>",
"        <strong>",
"         Pertussis",
"        </strong>",
"        (also called &ldquo;whooping cough&rdquo;) &mdash; People with hepatitis C should get 1 dose of this vaccine at some point during their adult life. Sometimes the vaccine for pertussis comes in the same shot as the diphtheria and tetanus vaccines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19918674\">",
"      <span class=\"h1\">",
"       Why are vaccines so important when you have hepatitis C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Infections can be hard on anyone who already has another infection or is sick in other ways. People with hepatitis C have an infection caused by a virus. This is called &ldquo;viral hepatitis.&rdquo;",
"     </p>",
"     <p>",
"      When you have hepatitis C, getting infected with a second type of viral hepatitis can be very serious. That&rsquo;s because your liver is already not working as well as it should. Another viral hepatitis infection can shut down your liver completely.",
"     </p>",
"     <p>",
"      Having a second infection, even if it&rsquo;s not another form of hepatitis, can also be serious when you have hepatitis C. That&rsquo;s because your body and your immune system (which fights infection) are weak. Plus, your liver might not be working right because of your hepatitis, so your body is already having a hard time staying healthy.",
"     </p>",
"     <p>",
"      Vaccines can cause side effects, such as soreness where you get the shot. But the benefits of the vaccines are far greater than the downsides.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19918681\">",
"      <span class=\"h1\">",
"       How do I find out if I have had all the vaccines I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your main doctor or nurse if you have been tested for viral hepatitis. People can have more than 1 form of viral hepatitis. Then ask if you have had all the vaccines you need. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19918717\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=see_link\">",
"       Patient information: Hepatitis A (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       Patient information: Hepatitis C (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"       Patient information: Hepatitis A (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       Patient information: Hepatitis B (Beyond the Basics)",
"      </a>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/45/1746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16407 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1746=[""].join("\n");
var outline_f1_45_1746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19918667\">",
"      Which vaccines do people with hepatitis C need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19918674\">",
"      Why are vaccines so important when you have hepatitis C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19918681\">",
"      How do I find out if I have had all the vaccines I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19918717\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=related_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=related_link\">",
"      Patient information: Hepatitis A (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1747="Epiglottitis subtle";
var content_f1_45_1747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child with less severe presentation of acute epiglottitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although not widely appreciated, epiglottitis caused by Haemophilus influenzae type b varies widely along the spectrum of severity. This one-year-old infant appears mildly anxious but looks much less toxic than patients with the \"classic\" presentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1747=[""].join("\n");
var outline_f1_45_1747=null;
var title_f1_45_1748="Potassium bicarbonate and potassium citrate (effervescent): Drug information";
var content_f1_45_1748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate and potassium citrate (effervescent): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19428?source=see_link\">",
"    see \"Potassium bicarbonate and potassium citrate (effervescent): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effer-K&reg;;",
"     </li>",
"     <li>",
"      Klor-Con&reg;/EF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses expressed as mEq of potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Normal daily requirement:",
"     </b>",
"     40-100 mEq/day or 1-2 mEq/kg/day (unlabeled dose; Mirtallo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypokalemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention: 10-80 mEq/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 40-100 mEq/day in 2-4 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     For asymptomatic mild hypokalemia, generally recommended to limit doses to 20-25 mEq/dose to avoid GI discomfort.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet for solution, oral [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effer-K&reg;:  Potassium 10 mEq [unflavored and cherry vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effer-K&reg;:  Potassium 20 mEq [unflavored and orange cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effer-K&reg;:  Potassium 25 mEq [unflavored, orange, lemon citrus, and cherry berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg;/EF: Potassium 25 mEq [sugar free; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16040805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dissolve tablet completely in 3-4 ounces of cold water or juice. May further dilute if GI adverse effects occur.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia, particularly when it is necessary to avoid chloride or the acid/base status requires bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Klor-Con&reg; may be confused with Klaron&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia and associated manifestations (eg, cardiac arrhythmias, etc)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperkalemia; concomitant use of potassium-sparing diuretics or potassium supplements",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic acidosis: Patients with hypokalemia accompanied by metabolic acidosis should be treated with an alkalinizing potassium salt.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Avoid with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACE inhibitors, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F211760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, effervescent",
"     </b>",
"     (Effer-K Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (30): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq (30): $14.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mEq (30): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, effervescent",
"     </b>",
"     (Klor-Con/EF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mEq (30): $15.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, effervescent",
"     </b>",
"     (Potassium Bicarbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mEq (30): $9.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, magnesium (to facilitate potassium repletion), and bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum potassium: 3.5-5.2 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is needed for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from upper GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1748/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9794 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1748=[""].join("\n");
var outline_f1_45_1748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211765\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211778\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211774\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211754\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211738\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16040805\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211756\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211785\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211776\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211759\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211742\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299915\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211747\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211749\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287300\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287302\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211760\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211752\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203078\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211741\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211758\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19428?source=related_link\">",
"      Potassium bicarbonate and potassium citrate (effervescent): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1749="Condylomata lata of syphilis";
var content_f1_45_1749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condylomata lata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Moist, gray papules that resemble condylomata acuminata are present on the perianal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1749=[""].join("\n");
var outline_f1_45_1749=null;
var title_f1_45_1750="Induced fetal demise";
var content_f1_45_1750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induced fetal demise",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Anna K Sfakianaki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Joshua Copel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1750/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/45/1750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induced fetal demise (also called iatrogenic fetal demise, feticide or fetocide) refers to the injection of a pharmacologic agent into a fetus to cause its demise. The procedure is usually performed as an adjunct to mid to late second trimester termination of pregnancy, but is also performed for selective or nonselective reduction of one or more fetuses in a multiple gestation. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39065?source=see_link\">",
"     \"Multifetal pregnancy reduction and selective termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Facilitation of abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, softening and loosening of fetal tissues and hormonal changes related to fetal demise should facilitate subsequent uterine evacuation. This has not been studied rigorously; however, the available data regarding pregnancy termination after induced fetal demise have not consistently observed a reduction in the duration of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with placenta previa undergoing medical termination of pregnancy, a case-control study including 15 pregnancies reported that preinduction feticide decreased the risk of transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/4\">",
"     4",
"    </a>",
"    ]. This finding needs to be confirmed in larger trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient/provider preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, standard methods of pregnancy termination via labor induction do not ensure fetal demise during the procedure. A live birth in this setting can be psychologically and emotionally difficult for the family and staff; feticide removes this possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In a randomized placebo controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    to facilitate late second-trimester abortion, 91 percent of patients indicated that they preferred their fetuses be dead prior to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/1\">",
"     1",
"    </a>",
"    ]. This has also been our experience; we have observed that patients who undergo abortion in the late second trimester are very amenable to induced fetal demise.",
"   </p>",
"   <p>",
"    Providers also generally favor induced fetal demise prior to the abortion procedure, for all of the reasons cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard methods of pregnancy termination via labor induction do not ensure fetal demise during the procedure. In many states, any birth with signs of life mandates neonatal intervention and resuscitation. Induced fetal demise prior to pregnancy termination assures stillbirth and thus avoids the possibility of resuscitation or litigation related to survival of a neonate delivered as a result of induced abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2007, the Supreme Court upheld the Partial Birth Abortion Act of 2003, which defines 'partial-birth abortion' as when \"the person performing the abortion deliberately and intentionally vaginally delivers a living fetus for the purpose of performing an overt act that the person knows will kill the partially delivered living fetus&rdquo;. While 'partial-birth abortion' is not a medically recognized procedure, the procedure that is most likely affected by this legislation is the intact dilatation and evacuation (D&amp;E). Feticide prior to D&amp;E assures compliance with this law.",
"   </p>",
"   <p>",
"    Many physicians providing second trimester termination require induction of fetal demise prior to D&amp;E or medical abortion. Ethicists advise that this requirement is the decision of the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Third trimester abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain perception requires peripheral sensory neural tissue that senses painful stimuli, cortical pathways that transmit pain signals to the brain, and development of higher cortical functions that can interpret the pain signals. The gestational age at which neural maturation is sufficiently developed to allow the fetus to perceive pain has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. A systematic multidisciplinary review of available evidence concluded that fetal pain perception is unlikely before the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/10\">",
"     10",
"    </a>",
"    ]. In areas where abortion is performed during the third trimester, induction of fetal demise prior to the procedure avoids the possibility that the fetus might experience pain during termination of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal medication allergy is a contraindication to induced fetal demise. There are no other absolute contraindications. The procedure requires a willing patient and skilled practitioner. Intracardiac injection requires more expertise than intraamniotic or intrafetal procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    are the most common drugs used to induce fetal asystole.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    has also been tried, but experience is limited to one study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    can be injected either intraamniotically or directly into the fetal heart or umbilical vein to induce demise. Both techniques appear to be equally effective, but intraamniotic injection is technically easier than intrafetal. A randomized trial (n = 52) comparing the two routes of administration found similar rates of fetal demise (intraamniotic: 85 percent; intrafetal: 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/13\">",
"     13",
"    </a>",
"    ]. Two different digoxin doses were also compared in the trial, with no significant difference in rates of fetal demise with 1.0 mg and 1.5 mg (92 and 81 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potassium chloride",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    (KCl) is injected into the fetal heart or umbilical vein to induce fetal death. In the largest series describing the use of KCl for feticide, 239 left ventricular injections at 17 to 24 weeks of gestation were performed with 100 percent success [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/14\">",
"     14",
"    </a>",
"    ]. No procedure took longer than five minutes. Three small series involving KCl injection into the umbilical vein reported success rates ranging from 87 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In these series, no maternal electrocardiographic modifications were observed and maternal plasma potassium levels did not show any significant variation throughout the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, maternal cardiac arrest after attempted fetal intracardiac injection of potassium chloride has been reported (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Side effects and complications'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Sterile drapes",
"     </li>",
"     <li>",
"      Sterilizing solution, such as povidone-iodine swab sticks, to prepare the surgical site",
"     </li>",
"     <li>",
"      Local anesthetic (eg, 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      solution)",
"     </li>",
"     <li>",
"      25 or 30 gauge needle attached to a 3 mL syringe to inject the local anesthetic. Local can be used if the treatment needle is 18 gauge or greater",
"     </li>",
"     <li>",
"      18, 20, or 22 gauge spinal needle attached to a 15 mL syringe",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      or KCl (2",
"      <span class=\"nowrap\">",
"       mEq/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Sterile saline solution to confirm needle location",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a number of reasons, most clinicians limit the procedure to fetuses greater than 20 weeks of gestation. Survival prior to this gestational age has not been reported. In addition, because of the fragile nature of the tissue at &lt;20 weeks, an intact D&amp;E usually cannot be performed, which obviates the need for a preprocedure fetal demise. The best obstetric estimate of gestational age is used to calculate the gestational age.",
"   </p>",
"   <p>",
"    The procedure is usually performed one to two days prior to surgical abortion, usually at the patient's preoperative visit for laminaria placement. It may be performed at any time prior to medical termination of pregnancy by induction of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All feticide procedures are performed under continuous ultrasound visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intracardiac injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its higher success rate, we prefer intracardiac injection of KCI to intraamniotic injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ; this is in agreement with Society of Family Planning clinical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/3\">",
"     3",
"    </a>",
"    ]. Use of a 22 gauge needle minimizes patient discomfort, but is more difficult to visualize and may bend in the fetus or an obese patient and thus be more difficult to maneuver. To minimize maternal discomfort from larger gauge needles, we use a 25 gauge needle to inject 2 to 5 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    solution into the maternal abdominal wall prior to the procedure.",
"   </p>",
"   <p>",
"    The spinal needle is directed into the fetal heart (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71131 \" href=\"UTD.htm?37/5/37968\">",
"     image 1",
"    </a>",
"    ). When the tip appears to be in the ventricle, we attempt to aspirate blood, which suggests but does not guarantee intracardiac placement. If the tip of the needle is not well-visualized, we also inject sterile saline until turbulence is seen, as turbulence at the needle tip confirms an intraventricular location. It is important to confirm correct placement as inadvertent injection into the maternal rather than the fetal compartment can produce serious adverse sequelae (see below).",
"   </p>",
"   <p>",
"    After correct placement is confirmed, we inject 5 to 15 mL of KCl solution (2",
"    <span class=\"nowrap\">",
"     mEq/mL),",
"    </span>",
"    keeping the needle in place until asystole occurs, which typically takes one to five minutes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72815 \" href=\"UTD.htm?4/16/4353\">",
"     image 2",
"    </a>",
"    ). KCL is usually injected in increments of 5 mL over a number of minutes. Asystole may occur abruptly, but usually takes two to three cardiac cycles.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    (1 mg) is an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intraumbilical vein injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feticide can also be accomplished by injection of KCL or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    into the umbilical vein. Compared to intracardiac injection, umbilical vein injection is technically more difficult and appears to be less successful in inducing asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intraamniotic injection of digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for intraamniotic injection is similar to that for amniocentesis, except 1.0 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is injected into the amniotic fluid after correct needle placement has been confirmed by aspiration of amniotic fluid. A 20 gauge needle is usually used, and maternal anesthesia is usually not necessary. Visualization of the fluid jet further confirms intraamniotic injection. As discussed above, this is the easiest procedure technically, but has a higher failure rate than intracardiac injection. This procedure is performed one to two days prior to the abortion, as, unlike KCl injection, asystole is not immediate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects and complications are rare. The range of findings is described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, eight women between 19 and 23 weeks of gestation received 1 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      via intraamniotic injection and then had serial serum digoxin levels determined for 48 hours, Holter cardiac monitoring performed for 24 hours, and laboratory assessments (digoxin level, prothrombin time, partial thromboplastin time, fibrinogen level) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/21\">",
"       21",
"      </a>",
"      ]. No rhythm or conduction abnormalities occurred, the peak digoxin concentration was in the low therapeutic range, and coagulation studies remained in the normal range.",
"     </li>",
"     <li>",
"      No adverse maternal events suggestive of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity were noted in another study that included over 1700 patients between 17 and 24 weeks of gestation who received intraamniotic or intrafetal digoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a placebo controlled randomized trial of intraamniotic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , a higher prevalence of maternal vomiting was noted in women who received intraamniotic digoxin than in those receiving saline (16 versus 3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Potassium chloride",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series of 239 intracardiac KCl injections, there were no maternal complications reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An isolated case of maternal cardiac arrest during an attempt at intracardiac KCl injection has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/18\">",
"       18",
"      </a>",
"      ]. Maternal toxicity may have resulted from maternal absorption of KCL when the needle passed through the fetus and into the maternal uterus and pelvis.",
"     </li>",
"     <li>",
"      Three series of patients who underwent intraumbilical vein administration of KCl reported no changes in postprocedural maternal electrocardiograms, potassium concentrations, or other adverse maternal outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SELECTIVE TERMINATION IN THE SECOND TRIMESTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective termination refers to the reduction of one anomalous or aneuploid fetus within a twin gestation. In dichorionic gestations, intracardiac injection of KCl is the preferred procedure because of its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/22\">",
"     22",
"    </a>",
"    ]. There are no data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    for induction of fetal demise in twin gestation. Intrafetal injection is likely comparable to intracardiac KCl injection with respect to complications. Intraamniotic injection could theoretically place the cotwin at risk due to perfusion across the membrane, and thus, should be avoided.",
"   </p>",
"   <p>",
"    In monochorionic pregnancies, fetal demise is induced by complete occlusion of the umbilical cord to avoid complications related to vascular anastomoses between the twins. A variety of techniques have been described, including bipolar cauterization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/23\">",
"     23",
"    </a>",
"    ], laser photocoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/24\">",
"     24",
"    </a>",
"    ], radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/25\">",
"     25",
"    </a>",
"    ], and mechanical occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1750/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39065?source=see_link&amp;anchor=H15#H15\">",
"     \"Multifetal pregnancy reduction and selective termination\", section on 'Selective termination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induced fetal demise prior to mid to late second trimester pregnancy termination assures stillbirth and thus avoids the possibility of resuscitation or litigation related to survival of a neonate delivered as a result of induced abortion. The procedure is well-received by patients and providers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       Potassium chloride",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      are the most commonly used drugs for inducing fetal demise. Potassium chloride is given to the fetus intravascularly (intracardiac or intraumbilical vein); digoxin can be administered intravascularly or intraamniotically. We suggest intracardiac potassium chloride rather than intracardiac digoxin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Evidence of the efficacy of this approach is better established than for other approaches. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Choice of agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious side effects and complications have not been reported as long as inadvertent maternal injection is avoided. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/1\">",
"      Jackson RA, Teplin VL, Drey EA, et al. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol 2001; 97:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/2\">",
"      Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol 1999; 94:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/3\">",
"      Diedrich J, Drey E, Society of Family Planning. Induction of fetal demise before abortion. Contraception 2010; 81:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/4\">",
"      Ruano R, Dumez Y, Cabrol D, Dommergues M. Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa--does feticide decrease postdelivery maternal hemorrhage? Fetal Diagn Ther 2004; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/5\">",
"      Fletcher JC, Isada NB, Pryde PG, et al. Fetal intracardiac potassium chloride injection to avoid the hopeless resuscitation of an abnormal abortus: II. Ethical issues. Obstet Gynecol 1992; 80:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/6\">",
"      Dommergues M, Cahen F, Garel M, et al. Feticide during second- and third-trimester termination of pregnancy: opinions of health care professionals. Fetal Diagn Ther 2003; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/7\">",
"      Isada NB, Pryde PG, Johnson MP, et al. Fetal intracardiac potassium chloride injection to avoid the hopeless resuscitation of an abnormal abortus: I. Clinical issues. Obstet Gynecol 1992; 80:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/8\">",
"      Chervenak FA, McCullough LB. An ethically justified practical approach to offering, recommending, performing, and referring for induced abortion and feticide. Am J Obstet Gynecol 2009; 201:560.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/9\">",
"      Giannakoulopoulos X, Sepulveda W, Kourtis P, et al. Fetal plasma cortisol and beta-endorphin response to intrauterine needling. Lancet 1994; 344:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/10\">",
"      Lee SJ, Ralston HJ, Drey EA, et al. Fetal pain: a systematic multidisciplinary review of the evidence. JAMA 2005; 294:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/11\">",
"      Mellor DJ, Diesch TJ, Gunn AJ, Bennet L. The importance of 'awareness' for understanding fetal pain. Brain Res Brain Res Rev 2005; 49:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/12\">",
"      Senat MV, Fischer C, Bernard JP, Ville Y. The use of lidocaine for fetocide in late termination of pregnancy. BJOG 2003; 110:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/13\">",
"      Nucatola D, Roth N, Gatter M. A randomized pilot study on the effectiveness and side-effect profiles of two doses of digoxin as fetocide when administered intraamniotically or intrafetally prior to second-trimester surgical abortion. Contraception 2010; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/14\">",
"      Pasquini L, Pontello V, Kumar S. Intracardiac injection of potassium chloride as method for feticide: experience from a single UK tertiary centre. BJOG 2008; 115:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/15\">",
"      Senat MV, Fischer C, Ville Y. Funipuncture for fetocide in late termination of pregnancy. Prenat Diagn 2002; 22:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/16\">",
"      Gill P, Cyr D, Afrakhtah M, et al. Induction of fetal demise in advanced pregnancy terminations: report on a funic potassium chloride protocol. Fetal Diagn Ther 1994; 9:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/17\">",
"      Bhide A, Sairam S, Hollis B, Thilaganathan B. Comparison of feticide carried out by cordocentesis versus cardiac puncture. Ultrasound Obstet Gynecol 2002; 20:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/18\">",
"      Coke GA, Baschat AA, Mighty HE, Malinow AM. Maternal cardiac arrest associated with attempted fetal injection of potassium chloride. Int J Obstet Anesth 2004; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/19\">",
"      Molaei M, Jones HE, Weiselberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception 2008; 77:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/20\">",
"      Hern WM, Zen C, Ferguson KA, et al. Outpatient abortion for fetal anomaly and fetal death from 15-34 menstrual weeks' gestation: techniques and clinical management. Obstet Gynecol 1993; 81:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/21\">",
"      Drey EA, Thomas LJ, Benowitz NL, et al. Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. Am J Obstet Gynecol 2000; 182:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/22\">",
"      Evans MI, Goldberg JD, Dommergues M, et al. Efficacy of second-trimester selective termination for fetal abnormalities: international collaborative experience among the world's largest centers. Am J Obstet Gynecol 1994; 171:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/23\">",
"      Robyr R, Yamamoto M, Ville Y. Selective feticide in complicated monochorionic twin pregnancies using ultrasound-guided bipolar cord coagulation. BJOG 2005; 112:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/24\">",
"      Lewi L, Gratacos E, Ortibus E, et al. Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies. Am J Obstet Gynecol 2006; 194:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/25\">",
"      Moise KJ Jr, Johnson A, Moise KY, Nickeleit V. Radiofrequency ablation for selective reduction in the complicated monochorionic gestation. Am J Obstet Gynecol 2008; 198:198.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1750/abstract/26\">",
"      Quintero RA, Romero R, Reich H, et al. In utero percutaneous umbilical cord ligation in the management of complicated monochorionic multiple gestations. Ultrasound Obstet Gynecol 1996; 8:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6819 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-C708E0D7D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1750=[""].join("\n");
var outline_f1_45_1750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Facilitation of abortion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient/provider preference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Legal issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Third trimester abortion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potassium chloride",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intracardiac injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intraumbilical vein injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intraamniotic injection of digoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Potassium chloride",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SELECTIVE TERMINATION IN THE SECOND TRIMESTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6819|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/5/37968\" title=\"diagnostic image 1\">",
"      Intracardiac KCl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/16/4353\" title=\"diagnostic image 2\">",
"      Asystole",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39065?source=related_link\">",
"      Multifetal pregnancy reduction and selective termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1751="Perioral rhytides";
var content_f1_45_1751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50746%7EDERM%2F76339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50746%7EDERM%2F76339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Perioral rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical wrinkles extending from the lip vermillion border are present. In this patient, the wrinkles are most evident on the lateral upper lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Mouth frown",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A downward turn of the corners of the mouth at rest (mouth frown) can occur as a normal feature of aging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1751=[""].join("\n");
var outline_f1_45_1751=null;
var title_f1_45_1752="Plica syndrome";
var content_f1_45_1752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Plica syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Jorge E Gomez, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1752/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/45/1752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10354459\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plica syndrome is a painful condition of the knee, often reported in runners and other athletes. The abnormal plica, an intraarticular band of thick, fibrotic tissue, may cause pain and a popping sensation by rubbing across either the medial femoral condyle or undersurface of the patella. Diagnosis can be difficult and requires careful consideration of other causes of anterior knee pain. Many patients respond to nonoperative treatment. For those failing nonoperative treatment, surgery is usually curative.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of plica syndrome will be reviewed here. The causes and diagnostic approach to knee pain in the young athlete and adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"       \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=see_link\">",
"       \"Causes of chronic knee pain in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"       \"Approach to the young athlete with acute knee pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"       \"Approach to the young athlete with chronic knee pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"       \"Evaluation of the active adult patient with knee pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354466\">",
"    <span class=\"h1\">",
"     ANATOMY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plicae are considered to be normal mesenchymal structures that represent remnants of the septations created by the various cavitations that coalesce to form the knee joint in utero. These septations begin to involute about the 12",
"    <sup>",
"     th",
"    </sup>",
"    week of fetal life, but they persist in up to 50 percent of individuals based upon autopsy findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The normal plica is seen arthroscopically to be a thin, vascular structure that is easily deformable with a probe, often appearing as a thin, narrow veil of tissue. An abnormal plica is thick, fibrotic, and relatively avascular, at least in its mid-portion, and is often taut and cord-like.",
"   </p>",
"   <p>",
"    There are four distinct types of plica based on their origin and insertion (",
"    <a class=\"graphic graphic_figure graphicRef83267 \" href=\"UTD.htm?26/39/27253\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The suprapatellar plica lies between the suprapatellar bursa and the knee joint [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/3\">",
"       3",
"      </a>",
"      ]. Incidence in arthroscopically operated knees approaches 87 to 91 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The medial plica (also called the medial shelf, plica synovialis mediopatellaris, plica alaris elongata, lion's bands, or Aoki edge) arises from the medial wall of the knee joint, passes down and around the medial femoral epicondyle, and inserts into the synovium surrounding the infrapatellar fat pad [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. This plica appears in 55 to 92 percent of arthroscopically knees depending on how the plica was defined [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The infrapatellar plica (or ligamentum mucosum) arises from the intercondylar notch and inserts into the synovium surrounding the infrapatellar fat pad [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. It is also commonly found at arthroscopy, with one series finding it in 86 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The lateral plica occurs rarely [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. It was found in less than 1 percent of 400 patients undergoing arthroscopy in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is common for an individual to have more than one plica. There are no distinct combinations of multiple plica [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medial plicae are most commonly symptomatic. As an example, in one series of 400 knees explored arthroscopically for knee pain without other major cartilage, ligament, or bone derangement, 72 percent of patients had medial patellar plicae [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these, 60 percent were type C (shelf) according to their classification.",
"   </p>",
"   <p>",
"    A classification system based upon morphology has been developed for each type of plica (ie, suprapatellar, medial patellar, infrapatellar, and lateral patellar). As an example, the following morphologic designations are common for medial patellar plica [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (A) Absent",
"     </li>",
"     <li>",
"      (B) Vestigial &ndash; A line of elevation 1 mm or less arises from the medial synovial shelf",
"     </li>",
"     <li>",
"      (C) Shelf-like &ndash; The medial synovium forms a complete fold with a sharp free margin",
"     </li>",
"     <li>",
"      (D) Reduplicated &ndash; Two or more shelves run parallel along the medial wall of the knee",
"     </li>",
"     <li>",
"      (E) Fenestrated &ndash; The shelf has a central defect",
"     </li>",
"     <li>",
"      (F) High-riding &ndash; A shelf occurs anterior and medial to the medial facet where it could not touch the femur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medial plicae are also described by the amount of contact with the medial femoral condyle as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not touching",
"     </li>",
"     <li>",
"      Contacting the condyle",
"     </li>",
"     <li>",
"      Widely covering the condyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Classification systems for suprapatellar, infrapatellar, and lateral patellar plica are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354473\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of symptomatic (presumably abnormal) plica is not known, primarily due to the absence of strict clinical criteria for making this diagnosis. However, it is described in a variety of age groups from children to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/2\">",
"     2",
"    </a>",
"    ]. Many experts suggest that plica syndrome is an under-diagnosed cause of anterior knee pain in adolescents and young adults. Estimates for the frequency of plica syndrome based upon small arthroscopic series of children, adolescents and young adults with acute knee pain range from 8 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. An abnormal medial plica was most commonly found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354480\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologically abnormal plica may develop after direct trauma, (eg, a direct blow to the knee or twisting injury), or following repetitive knee movements that cause injury and inflammation of the plica with subsequent fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Intraarticular abnormalities, such as loose foreign bodies osteochondritis dissecans, or inflammatory arthritis may also inflame a plica. The resulting thickening and loss of elasticity of the structure causes it to snap over the medial femoral condyle causing synovitis, chondral damage, and pain.",
"   </p>",
"   <p>",
"    The plica syndrome has most often been reported in runners in whom repetitive motion combined with abnormal motion or biomechanical stress at the knee joint causes excessive anterior contact between the medial plica and either the medial femoral condyle or medial patellar facet. Symptomatic plicae also occur in swimmers, rowers, cyclers, and basketball players [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/10\">",
"     10",
"    </a>",
"    ]. Furthermore, a plica may become symptomatic in the absence of a history of trauma or intraarticular pathology, especially in patients with a knee valgus. (See",
"    <a class=\"local\" href=\"#H10354502\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354487\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354495\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with symptomatic plica often complain of anterior and medial knee pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients report that this pain began with a direct blow or twisting injury to the knee. They frequently describe the pain as worse with activity, such as running, squatting, going up or down stairs, or kneeling, and after prolonged sitting (cinema sign). The pain is often accompanied by a popping sensation with knee flexion. Patients may also report clicking, catching, knee pseudo-locking (false locking), or giving way. In most patients only one knee is involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354502\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings are often nonspecific and include the following in symptomatic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpable fibrotic fold or cord over the medial femoral condyle (medial plica) when the knee is flexed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/11\">",
"       11",
"      </a>",
"      ]; this finding is not specific for medial plica syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vague tenderness over the medial femoral condyle or medial patellar facet",
"     </li>",
"     <li>",
"      Soft tissue swelling just medial to the patellar border",
"     </li>",
"     <li>",
"      Because of pain during knee flexion, tightness in the hamstring, quadriceps, and gastrocnemius muscles with limited dorsiflexion of the foot [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Quadriceps atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Weakness of hip abduction similar to patients with patellofemoral pain syndrome (see",
"      <a class=\"local\" href=\"#H10354560\">",
"       'Patellofemoral pain syndrome'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Effusion; joint swelling typically indicates the presence of chondral injury associated with a plica and is frequent in adults but uncommon in adolescent patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reproduction of clicking or popping with active or passive range of motion; this finding is rare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above clinical findings, the following provocative tests are helpful in making a diagnosis of plica syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medial patellar plica (MPP) test",
"      </strong>",
"      &ndash; With the patient in the supine position, pressure is applied with the thumb over the inferior and medial aspect of the patellofemoral joint with the aim of interposing the medial plica between the medial patellar facet and the medial condyle [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/16\">",
"       16",
"      </a>",
"      ]. While maintaining this pressure, the knee is passively flexed from 0 to 90 degrees (",
"      <a class=\"graphic graphic_figure graphicRef83265 \" href=\"UTD.htm?18/51/19248\">",
"       figure 2",
"      </a>",
"      ). Somewhere between 30 and 45 degrees the medial pain is reproduced, ostensibly by the plica being pinched between the medial patellar facet and the medial condyle, and there may be a clicking or popping sensation.",
"      <br/>",
"      <br/>",
"      In a prospective study of 166 patients (65 with medial plica syndrome), the MPP test had a sensitivity, specificity, and positive predictive value of 90, 89, and 79 percent, respectively when performed by an orthopedist [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Knee extension text",
"      </strong>",
"      &ndash; With the patient supine, starting with the knee at 90 degrees of flexion, the patella is forced medially while the examiner internally rotates the lower leg then slowly extends the knee (",
"      <a class=\"graphic graphic_figure graphicRef83266 \" href=\"UTD.htm?2/12/2241\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/18\">",
"       18",
"      </a>",
"      ]. The test is positive if the patient&rsquo;s pain and popping are reproduced between 60 and 45 degrees of flexion. This test was positive in all of 136 patients with symptomatic plicae in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/14\">",
"       14",
"      </a>",
"      ]. However, in the author&rsquo;s experience, the knee extension test is helpful but not always positive in patients with plica syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genu valgus or knock knees will tend to worsen the tension of the medial plica as it passes obliquely over the medial femoral condyle in the coronal plane and is a predisposing finding.",
"   </p>",
"   <p>",
"    Abnormalities at the ankle and hip that cause valgus angulation at the knee during activity may contribute to the pain and clicking. These include weakness of the hip abductors or tight hip adductors.",
"   </p>",
"   <p>",
"    Predisposing abnormalities of the foot include loss of longitudinal arch from posterior tibial dysfunction or spring ligament insufficiency leading to resting pronation at midfoot, subtalar subluxation or calcaneal valgus leading to these changes at the rear foot, or congenital changes such as tarsal coalitions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354509\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plica syndrome is a clinical and arthroscopic diagnosis. However, imaging is frequently required to exclude other causes of knee pain. The type of imaging performed is determined by the leading alternative diagnoses. (See",
"    <a class=\"local\" href=\"#H10354552\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the patient with plica syndrome without other intraarticular or joint pathology, such as synovitis, chondral injury or loose foreign body, plain radiographs of the knee are normal.",
"   </p>",
"   <p>",
"    Although arthrogram, routine ultrasound (US), and magnetic resonance imaging can all demonstrate the presence of plicae, they are unreliable in predicting which plica are pathologic at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, ultrasonography with medial and lateral patella manipulation in 88 patients with clinical findings suggestive of medial plica syndrome had a sensitivity, specificity, and diagnostic accuracy of 90, 83, and 88 percent respectively when compared to arthroscopic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, static knee US may identify other causes for anterior or medial knee pain that exclude the diagnosis of plica syndrome. However, ultrasonography is highly dependent upon experienced examiners who may not be routinely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354545\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of plica syndrome is primarily based upon clinical features and should only be made once other causes of knee pain have been excluded. It is suggested by the history of anterior and medial knee pain after direct trauma, twisting injury, or repetitive injury. The pain typically becomes worse with squatting, kneeling, going upstairs, or sitting for long periods of time (cinema sign). Clicking upon knee flexion may also occur.",
"   </p>",
"   <p>",
"    Physical findings are variable and nonspecific. In patients having a medial plica, there may be subtle soft tissue swelling just medial to the patellar border. Careful palpation with the knee at 90 degrees of flexion may reveal a firm, tender ridge of tissue running either parallel or slightly obliquely to the medial border of the patellar. Examination may also reveal tight quadriceps and hamstring muscles and positive medial patellar plica (",
"    <a class=\"graphic graphic_figure graphicRef83265 \" href=\"UTD.htm?18/51/19248\">",
"     figure 2",
"    </a>",
"    ) and knee extension (",
"    <a class=\"graphic graphic_figure graphicRef83266 \" href=\"UTD.htm?2/12/2241\">",
"     figure 3",
"    </a>",
"    ) tests. Imaging does not establish the diagnosis of plica syndrome but is primarily performed to exclude other knee pathology. (See",
"    <a class=\"local\" href=\"#H10354487\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10354552\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Arthroscopy provides a definitive diagnosis if a thickened, fibrotic plica is demonstrated, but is only performed when other diagnoses are considered or when conservative treatment fails. In patients with medial plica syndrome, intraoperative flexion of the knee causes the fibrotic plica to snap over the medial femoral condyle. (See",
"    <a class=\"local\" href=\"#H10354602\">",
"     'Initial treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354552\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354560\">",
"    <span class=\"h2\">",
"     Patellofemoral pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (or runner&rsquo;s knee) describes anterior knee pain involving the patella and retinaculum that may arise from overuse, improper patella tracking during extension, or trauma. Several clinical features overlap with plica syndrome including pain with increased activity, particularly going up and down stairs, during squatting, or after prolonged sitting. Patients with patellofemoral pain syndrome also often have tight hamstring, quadriceps, and calf muscles, evidence of excessive knee valgus with single-leg squat, and associated hip abductor weakness and hindfoot varus or mid-foot pronation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link&amp;anchor=H11#H11\">",
"     \"Patellofemoral pain syndrome\", section on 'Clinical presentation and examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike plica syndrome, patellofemoral pain syndrome does not typically manifest with clicking or popping unless there is an associated chondromalacia or subluxation of the patella. Effusion or synovitis does not usually occur, and the pain is usually localized to the medial or lateral patellar facets by direct palpation in full extension. Other features of patellofemoral pain syndrome and its treatment are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link&amp;anchor=H11#H11\">",
"     \"Patellofemoral pain syndrome\", section on 'Clinical presentation and examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link&amp;anchor=H17#H17\">",
"     \"Patellofemoral pain syndrome\", section on 'Initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354567\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with osteoarthritis of the patellofemoral joint may also localize pain to the anterior medial knee, and complain of crepitus and clicking. Pain on palpation is usually localized to the patellar facets, and the patellar grind test is positive for crepitus. The grind test is performed with the examiner applying downward pressure on the patella with the knee extended, as the patella is gently moved medially and laterally. Osteoarthritis may also manifest with synovitis or effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of osteoarthritis\", section on 'Knees'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical criteria for osteoarthritis of the knee include age &gt;50 years, morning stiffness for less than 30 minutes, crepitus on active knee movement, bony tenderness or enlargement, and no palpable warmth. Plain radiographs may show a decrease in cartilage space with adjacent osteophytes. This diagnosis is usually made based upon clinical criteria but may be definitively confirmed by arthroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and classification of osteoarthritis\", section on 'Osteoarthritis of the knee'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of osteoarthritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354574\">",
"    <span class=\"h2\">",
"     Patellar subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellar subluxation refers to excessive lateral movement of the patella and may occur as a result of trauma or in patients with laxity. These patients often complain of knee pain and popping or clicking, and occasionally knee swelling, stiffness, or catching.",
"   </p>",
"   <p>",
"    On physical examination, patients with patellar subluxation may have synovitis and effusion. Other findings of patellar subluxation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenderness localized to the adductor tubercle and patellar facets, especially the lateral facet.",
"     </li>",
"     <li>",
"      Abnormal patellar tracking including a positive jump-sign or j-sign (patella moves outward rather than upward with knee extension when the knee is straightened in the seated patient)",
"     </li>",
"     <li>",
"      Positive patellar apprehension test (contraction of the quadriceps in response to lateral passive displacement of the patella), although patients with hyperelasticity may have little apprehension in the authors&rsquo; experience.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of patellar subluxation is aimed at strengthening the quadriceps, principally the vastus medialis obliquus, and minimizing knee valgus by strengthening the hip abductors and by increasing flexibility of the hip adductors. Use of a patellar stabilizing orthosis is often helpful. Surgical procedures are also available to either release the tension from the lateral patellar retinaculum or reconstruct the medial patellofemoral ligament when conservative treatment has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354581\">",
"    <span class=\"h2\">",
"     Medial meniscus tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a medial meniscus tear will usually report an acute inciting event, often involving some torquing or rotational movement under stress without direct trauma. Patients with medial meniscus tears typically have tenderness along the medial joint line and discomfort or a catching sensation on provocative tests, such as the McMurray (",
"    <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"     figure 4",
"    </a>",
"    ), Apley, Thessaly, or bounce home tests (",
"    <a class=\"graphic graphic_figure graphicRef55603 \" href=\"UTD.htm?35/24/36239\">",
"     figure 5",
"    </a>",
"    ). Magnetic resonance imaging is sensitive for detecting medial meniscus tears but is only necessary if surgery is contemplated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H5#H5\">",
"     \"Meniscal injury of the knee\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H10#H10\">",
"     \"Meniscal injury of the knee\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354588\">",
"    <span class=\"h2\">",
"     Anserine bursitis or tendonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with anserine bursitis or tendonitis complains of medial knee pain and may report swelling. However, there is no clicking or popping, no catching or pseudo-locking. On physical examination, the tenderness is usually confined to the insertion of the pes anserinus tendon at the medial proximal tibia, and there is no evidence of intraarticular damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Anserine bursitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354595\">",
"    <span class=\"h2\">",
"     Osteochondritis dissecans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) presents with insidious onset of knee pain and a history of heavy activity, similar to some patients with the plica syndrome. Patients with OCD may also report swelling. If the osteochondral lesion is stable, the patient rarely reports clicking or popping. However, the location of the pain may be similar to the plica syndrome, as &gt;70 percent of these lesions occur on the medial femoral condyle. In some patients with OCD, there is palpable tenderness near the medial edge of the intercondylar notch with the knee in partial flexion. OCD is usually evident on plain films, although sometimes only with a tunnel view, whereas with plica the plain films are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H2510199#H2510199\">",
"     \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354602\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment for plica syndrome are to reduce pain, strengthen the knee extensor muscles (quadriceps), mitigate mechanical factors that produce excessive knee valgus, and return the patient to as high a level of function as possible. The acute phase of treatment during the first week focuses on pain control; the subsequent recovery phase focuses on modification of biomechanical deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776662\">",
"    <span class=\"h2\">",
"     Acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment during the first week of care includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Activity modification",
"      </strong>",
"      &ndash; Patients need to avoid activities that cause pain during rehabilitation. Most runners need to reduce running volumes and those with severe signs or symptoms (eg, limping) should curtail all running activities. Patients with less severe symptoms may modify their training by reducing the overall distance and avoiding running up hills or steps. Athletes can maintain aerobic fitness by using a stationary bicycle (recumbent or upright), an upper body cycle, or by swimming, water running, or other activities, provided they do not cause pain.",
"     </li>",
"     <li>",
"      <strong>",
"       Nonsteroidal antiinflammatory drugs (NSAIDs)",
"      </strong>",
"      &ndash; NSAIDs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every six hours, maximum dose 800 mg) may be used for short-term pain relief during the first three days. No studies have specifically evaluated the benefit of NSAIDs for the treatment of plica syndrome.",
"     </li>",
"     <li>",
"      <strong>",
"       Ice application",
"      </strong>",
"      &ndash; Although formal studies are lacking, applying ice to the medial knee is regarded by most experts as a key aspect of acute treatment of plica syndrome. The plica, being a superficial structure, requires ice applications of only 10 to 15 minutes duration three to four times per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776670\">",
"    <span class=\"h2\">",
"     Recovery phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment beyond the first week of care consists of physical therapy to address tightness and weakness of specific muscle groups and orthotics to correct heel valgus if present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776679\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited observational evidence from two small case series suggests that exercises to increase knee extensor strength and flexibility of the quadriceps, hip adductors (eg, adductor magnus), gastrocnemius, and hamstring muscles are successful in treating patients with plica syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776731\">",
"    <span class=\"h3\">",
"     Stretching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initial pain has subsided, we suggest that patients with plica syndrome perform daily or twice daily therapeutic stretching exercises of the quadriceps, hip adductors (eg, adductor magnus), gastrocnemius, and hamstring muscles under the guidance of physical therapists. Observational studies suggest that 40 to 78 percent of patients with a clinical diagnosis of plica syndrome will return to their previous level of function without pain within three to six months of initiating stretching [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In one study, the patients with the greatest gains in flexibility had better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776796\">",
"    <span class=\"h3\">",
"     Quadriceps strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initial pain has subsided, we suggest that patients with plica syndrome perform quadriceps strengthening exercises under the guidance of a physical therapist. In one series of 63 patients with a clinical diagnosis of plica syndrome, knee extension exercises in addition to stretching of the quadriceps, hip adductors (eg, adductor magnus), gastrocnemius, and hamstring muscles resulted in a return to normal function in 86 percent of patients within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776848\">",
"    <span class=\"h3\">",
"     Treatment of knee valgus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mechanical factors producing excessive knee valgus as determined by a single leg squat, including weak hip abductors, tight hip adductors and iliotibial band, should also undergo physical therapy to correct these problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776855\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with plica syndrome exacerbated by heel valgus and mid-foot pronation should receive an orthotic with a medial wedge.",
"   </p>",
"   <p>",
"    There is little evidence to support the use of intraarticular injection of corticosteroid to treat plica syndrome. This treatment should",
"    <strong>",
"     not",
"    </strong>",
"    be routinely performed. However, in our experience, corticosteroid injection directly into the painful plica when the plica is readily palpable may be helpful when the above conservative measures have not provided relief.",
"   </p>",
"   <p>",
"    Compression knee sleeves or braces can be offered; however in the author&rsquo;s experience they may increase pressure on the anterior-medial knee thereby worsening pain, especially in patients with medial plica syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776891\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be followed at least monthly during the recovery phase and more frequently if improvement is lacking. If the patient reports recurrence or persistence of knee pain, assess the patient's compliance with and response to the prescribed therapy.",
"   </p>",
"   <p>",
"    Have the patient explain in detail the exercises they have been doing. When did they first see the physical therapist? How many times a week do they go to physical therapy? How often do they do their home program? Have the patient demonstrate some of the exercises. Ask about their tolerance of the therapy and quantify their cardiovascular workouts (eg, \"I can ride the stationary bike for 10 minutes until my knee hurts\" versus \"I'm still running 25 miles per week\"). Ask about previously aggravating activities and assess improvement.",
"   </p>",
"   <p>",
"    If there is improvement, continue physical therapy until the patient can perform all exercises without pain, and then slowly reintroduce activities which previously caused pain (eg, running). Increase activity levels in a gradual, step-wise progression, until the patient achieves the desired level. If symptoms are unchanged and the patient appears to be compliant with both therapy and activity modification, re-examine the patient to confirm the original diagnosis. Perform additional imaging to evaluate for other diagnoses that commonly cause antero-medial knee pain as clinically indicated. (See",
"    <a class=\"local\" href=\"#H10354552\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the compliant patient has not improved with three to six months of therapy, then orthopedic consultation is indicated to assess for another cause for the pain and, if plica syndrome is confirmed, to reinforce the physical therapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12776915\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon small observational studies, surgical intervention, consisting of complete arthroscopic excision of the fibrotic plica, is potentially indicated when 12 months of conservative treatment, consisting of stretching of the quadriceps, hip adductors (eg, adductor magnus), gastrocnemius, and hamstring muscles and strengthening of the quadriceps muscles has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1752/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Operative treatment provides significant improvement in 87 to 94 percent of patients.",
"   </p>",
"   <p>",
"    During arthroscopy, the entire joint must be evaluated for other fibrotic plica, chondral injury to the undersurface of the patella and the medial femoral condylar articular surface, as well as other possible derangements (eg, arthrosis, loose bodies, or osteochondritis dissecans) that may have led to the development of a pathologic plica.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10354516\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A plica is an embryonic remnant commonly present in the population. Normally it consists of a thin, vascular, pliable band of tissue that originates from the synovial wall and crosses the synovial joint. It may be located in the suprapatellar, medial, infrapatellar, or lateral compartments of the knee joint (",
"      <a class=\"graphic graphic_figure graphicRef83267 \" href=\"UTD.htm?26/39/27253\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10354473\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10354466\">",
"       'Anatomy and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A plica becomes abnormal when, as a result of direct blunt trauma to the knee, repetitive injury, or irritation from some other intraarticular abnormality, it becomes thickened, fibrotic, avascular, and taut. Symptoms occur as the nonpliable band either snaps over the medial femoral condyle, or is entrapped between the patella and femoral condyle. (See",
"      <a class=\"local\" href=\"#H10354480\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of plica syndrome is suggested by the history of anterior and medial knee pain after direct trauma, twisting injury, or repetitive injury. The pain typically becomes worse with squatting, kneeling, going upstairs, or sitting for long periods of time (cinema sign). Clicking upon knee flexion may also occur. Physical findings are variable. In patients having a medial plica, there may be subtle soft tissue swelling just medial to the patellar border. Careful palpation with the knee at 90 degrees of flexion may reveal a firm, tender ridge of tissue running either parallel or slightly obliquely to the medial border of the patellar. Examination may also reveal tight quadriceps and hamstring muscles, and positive medial patellar plica (",
"      <a class=\"graphic graphic_figure graphicRef83265 \" href=\"UTD.htm?18/51/19248\">",
"       figure 2",
"      </a>",
"      ) and knee extension (",
"      <a class=\"graphic graphic_figure graphicRef83266 \" href=\"UTD.htm?2/12/2241\">",
"       figure 3",
"      </a>",
"      ) tests. (See",
"      <a class=\"local\" href=\"#H10354545\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging does not establish the diagnosis of plica syndrome but is primarily performed to exclude other knee pathology. (See",
"      <a class=\"local\" href=\"#H10354487\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10354552\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute phase of treatment of plica syndrome focuses on reduction of pain through activity modification, application of ice, and short-term administration of nonsteroidal antiinflammatory drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12776662\">",
"       'Acute phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the initial pain has subsided, we suggest that patients with plica syndrome perform the following under the guidance of physical therapists (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Daily or twice daily therapeutic stretching exercises of the quadriceps, hip adductors (eg, adductor magnus), gastrocnemius, and hamstring muscles. (See",
"      <a class=\"local\" href=\"#H12776731\">",
"       'Stretching'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quadriceps strengthening exercises under the guidance of physical therapists. (See",
"      <a class=\"local\" href=\"#H12776796\">",
"       'Quadriceps strengthening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mechanical factors producing excessive knee valgus as determined by a single leg squat, including weak hip abductors, tight hip adductors and iliotibial band, should also undergo physical therapy to correct these problems. (See",
"      <a class=\"local\" href=\"#H12776848\">",
"       'Treatment of knee valgus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with plica syndrome exacerbated by heel valgus and mid-foot pronation should receive an orthotic with a medial wedge. (See",
"      <a class=\"local\" href=\"#H12776855\">",
"       'Adjunctive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corticosteroid injections should",
"      <strong>",
"       not",
"      </strong>",
"      be routinely performed. However, corticosteroid injection directly into the painful plica when the plica is readily palpable may be helpful when the above conservative measures have not provided relief. Compression knee sleeves may be used as adjunctive therapy with variable results. (See",
"      <a class=\"local\" href=\"#H12776855\">",
"       'Adjunctive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient compliant with activity restrictions and physical therapy exercises has not improved within three to six months of therapy, then orthopedic or sports medicine consultation is indicated to assess for another cause for the pain and, if plica syndrome is confirmed, to reinforce the physical therapy regimen. Surgical intervention, consisting of complete arthroscopic excision of the fibrotic plica, is potentially indicated when 12 months of conservative treatment has failed. (See",
"      <a class=\"local\" href=\"#H12776915\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/1\">",
"      Camanho GL. Treatment of pathological synovial plicae of the knee. Clinics (Sao Paulo) 2010; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/2\">",
"      Bellary SS, Lynch G, Housman B, et al. Medial plica syndrome: a review of the literature. Clin Anat 2012; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/3\">",
"      Kent M, Khanduja V. Synovial plicae around the knee. Knee 2010; 17:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/4\">",
"      Nakayama A, Sugita T, Aizawa T, et al. Incidence of medial plica in 3,889 knee joints in the Japanese population. Arthroscopy 2011; 27:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/5\">",
"      Kim SJ, Choe WS. Arthroscopic findings of the synovial plicae of the knee. Arthroscopy 1997; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/6\">",
"      Brush&oslash;j C, H&ouml;lmich P, Nielsen MB, Albrecht-Beste E. Acute patellofemoral pain: aggravating activities, clinical examination, MRI and ultrasound findings. Br J Sports Med 2008; 42:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/7\">",
"      Pihlajam&auml;ki HK, Kuikka PI, Lepp&auml;nen VV, et al. Reliability of clinical findings and magnetic resonance imaging for the diagnosis of chondromalacia patellae. J Bone Joint Surg Am 2010; 92:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/8\">",
"      Sarpel Y, Ozkan C, Torul E, et al. Arthroscopy of the knee in pre-adolescent children. Arch Orthop Trauma Surg 2007; 127:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/9\">",
"      Schindler OS. Synovial plicae of the knee. Current Orthopedics 2004; 18:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/10\">",
"      Boles CA, Martin DF. Synovial plicae in the knee. AJR Am J Roentgenol 2001; 177:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/11\">",
"      Muse GL, Grana WA, Hollingsworth S. Arthroscopic treatment of medial shelf syndrome. Arthroscopy 1985; 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/12\">",
"      Weckstr&ouml;m M, Niva MH, Lamminen A, et al. Arthroscopic resection of medial plica of the knee in young adults. Knee 2010; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/13\">",
"      Curtin B, Abbott D, Nyland J, Caborn D. Bilateral bucket handle medial plica in an adolescent. Knee Surg Sports Traumatol Arthrosc 2010; 18:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/14\">",
"      Amatuzzi MM, Fazzi A, Varella MH. Pathologic synovial plica of the knee. Results of conservative treatment. Am J Sports Med 1990; 18:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/15\">",
"      Guney A, Bilal O, Oner M, et al. Short- and mid-term results of plica excision in patients with mediopatellar plica and associated cartilage degeneration. Knee Surg Sports Traumatol Arthrosc 2010; 18:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/16\">",
"      Kim SJ, Jeong JH, Cheon YM, Ryu SW. MPP test in the diagnosis of medial patellar plica syndrome. Arthroscopy 2004; 20:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/17\">",
"      Kim SJ, Lee DH, Kim TE. The relationship between the MPP test and arthroscopically found medial patellar plica pathology. Arthroscopy 2007; 23:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/18\">",
"      Pipkin G. Knee injuries: the role of the suprapatellar plica and suprapatellar bursa in simulating internal derangements. Clin Orthop Relat Res 1971; 74:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/19\">",
"      Jee WH, Choe BY, Kim JM, et al. The plica syndrome: diagnostic value of MRI with arthroscopic correlation. J Comput Assist Tomogr 1998; 22:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1752/abstract/20\">",
"      Paczesny L, Kruczynski J. Medial plica syndrome of the knee: diagnosis with dynamic sonography. Radiology 2009; 251:439.",
"     </a>",
"    </li>",
"    <li>",
"     Steiner T, Parker RD. Subluxation and dislocation - Patellofemoral instability: recurrent dislocation of the patella. In: Orthopedic Sports Medicine, 3rd, DeLee JC, Drez D, Miller MD.  (Eds), Saunders, Philadelphia 2009. p.1548.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17160 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1752=[""].join("\n");
var outline_f1_45_1752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10354516\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354459\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354466\">",
"      ANATOMY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354473\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354480\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354487\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354495\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354502\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354509\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354545\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354552\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354560\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354567\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354574\">",
"      Patellar subluxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354581\">",
"      Medial meniscus tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354588\">",
"      Anserine bursitis or tendonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10354595\">",
"      Osteochondritis dissecans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354602\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12776662\">",
"      Acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12776670\">",
"      Recovery phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12776679\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12776731\">",
"      - Stretching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12776796\">",
"      - Quadriceps strengthening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12776848\">",
"      - Treatment of knee valgus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12776855\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12776891\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12776915\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10354516\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/17160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17160|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/39/27253\" title=\"figure 1\">",
"      Synovial plicae anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/51/19248\" title=\"figure 2\">",
"      Medial patellar plica test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2241\" title=\"figure 3\">",
"      Knee extension test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6676\" title=\"figure 4\">",
"      McMurray test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/24/36239\" title=\"figure 5\">",
"      Bounce home test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=related_link\">",
"      Causes of chronic knee pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=related_link\">",
"      Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1753="Mifepristone: Drug information";
var content_f1_45_1753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mifepristone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/15/2295?source=see_link\">",
"    see \"Mifepristone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Korlym&trade;;",
"     </li>",
"     <li>",
"      Mifeprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Abortifacient;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Hormone Antagonist;",
"     </li>",
"     <li>",
"      Antiprogestin;",
"     </li>",
"     <li>",
"      Cortisol Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperglycemia in patients with Cushing&rsquo;s syndrome (Korlym&trade;):",
"     </b>",
"     Oral: Initial dose: 300 mg once daily. Dose may be increased in 300 mg increments at intervals of &ge;2-4 weeks based on tolerability and symptom control. Maximum dose: 1200 mg once daily, not to exceed 20 mg/kg/day. If treatment is interrupted, reinitiate at 300 mg/day or a dose lower than the dose that caused the treatment to be stopped if interruption due to adverse reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment with concurrent use of strong CYP450 inhibitor therapy (eg, ketoconazole):",
"     </i>",
"     Maximum dose 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Termination of pregnancy (Mifeprex&reg;):",
"     </b>",
"     Oral: Treatment consists of 3 office visits by the patient; the patient must read medication guide and sign patient agreement prior to treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Day 1 (mifepristone administration):",
"     </i>",
"     600 mg (three 200 mg tablets) taken as a single dose under physician supervision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Day 3 (misoprostol administration):",
"     </i>",
"     Patient must return to the healthcare provider 2 days following administration of mifepristone; unless abortion has occurred (confirmed using ultrasound or clinical examination): Misoprostol 400 mcg (two 200 mcg tablets);",
"     <b>",
"      Note:",
"     </b>",
"     Patient may need treatment for cramps or gastrointestinal symptoms at this time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Day 14  (post-treatment exam):",
"     </i>",
"     Patient must return to the healthcare provider ~14 days after administration of mifepristone; confirm complete termination of pregnancy by ultrasound or clinical exam. Surgical termination is recommended to manage treatment failures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Termination of pregnancy (unlabeled dosing):",
"     </i>",
"     Mifepristone 200 mg orally followed by misoprostol 800 mcg vaginally 24-48 hours later (ACOG, 2005; FIGO, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningioma, unresectable (unlabeled use; refer to individual protocols):",
"     </b>",
"     Oral: Mifepristone 200 mg/day, continue based on toxicity and response (Grunberg, 1991)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperglycemia in patients with Cushing&rsquo;s syndrome:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hyperglycemia in patients with Cushing&rsquo;s syndrome: Maximum dose 600 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Following doses of 1200 mg/day for 7 days in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute), exposure to mifepristone and its metabolites was increased and a large variability in exposure was observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Termination of pregnancy: No dosage adjustment provided in manufacturer's labeling (has not been studied)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F196826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hyperglycemia in patients with Cushing&rsquo;s syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Maximum dose 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Following single and multiple doses of 600 mg/day in patients with moderate hepatic impairment (Child-Pugh class B), a large variability in exposure to mifepristone and its metabolites was observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Termination of pregnancy: No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution due to CYP3A4 metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Korlym&trade;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mifeprex&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Korlym&trade; is only available through a restricted access program. For prescriber registration and patient enrollment forms, please refer to https://www.korlymspark.com/login.aspx?ReturnUrl=%2fdefault.aspx or call 1-855-4Korlym (1-855-456-7596).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Mifeprex&reg;: As a requirement of the REMS program, a medication guide must be given to the patient prior to receiving the medication. In addition, the manufacturer recommends distributing a patient agreement form which must be signed by the patient and prescriber confirming the patient&rsquo;s agreement to terminate her pregnancy.  A signed copy of the patient agreement should be kept in the patient&rsquo;s medical record.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mifeprex&reg; is only available direct from Danco Laboratories' distributor. To obtain the product, please refer to, file://www.earlyoptionpill.com, or call 1-877-432-7596.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Investigators wishing to obtain the agent for use in oncology patients must apply for a patient-specific IND from the FDA.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Korlym&trade;",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294245.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294245.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mifeprex&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088643.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088643.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13897500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyperglycemia in patients with Cushing&rsquo;s syndrome: Administer as a single daily dose with a meal. Tablets should be swallowed whole, not crushed, split, or chewed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Termination of pregnancy: To be taken as a single dose under physician supervision",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Korlym&trade;: To control hyperglycemia occurring secondary to hypercortisolism in patients with endogenous Cushing&rsquo;s syndrome who have type 2 diabetes mellitus or glucose intolerance and who failed surgery or who are not surgical candidates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifeprex&reg;: Medical termination of intrauterine pregnancy, through day 49 of pregnancy. Patients may need treatment with misoprostol and possibly surgery to complete therapy.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F196844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of unresectable meningioma; has been studied in the treatment of breast cancer and ovarian cancer; termination of pregnancy &le;63 days of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mifeprex&reg; may be confused with Mirapex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mifepristone may be confused with misoprostol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adverse events associated with treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (26%), hypertension (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (48%), headache (44%), dizziness (22%), pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (34% to 44%), endometrial hypertrophy (38%), thyroid function tests abnormal (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (48%), vomiting (26%), appetite decreased (20%), xerostomia (18%), diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal bleeding (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (30%), back pain (16%), myalgia (14%), extremity pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (16%), sinusitis (14%), nasopharyngitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, pitting edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (10%), somnolence (10%), insomnia, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (10%), constipation (10%), abdominal pain, GI reflux",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage, metrorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flank pain, malaise, musculoskeletal chest pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% or frequency not defined: Adrenal insufficiency (4%), pruritus (4%), rash (4%), HDL cholesterol decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adverse events associated with treatment for termination of pregnancy:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Vaginal bleeding and uterine cramping are expected to occur when this medication is used to terminate a pregnancy; ~90% of women using this medication for this purpose also report adverse reactions on day 3 after the procedure. Bleeding or spotting occurs in most women for a period of 9-16 days. Up to 8% of women will experience some degree of bleeding or spotting for 30 days or more. In some cases, bleeding may be prolonged and heavy, potentially leading to hypovolemic shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 31%), dizziness (1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (cramping) (96%), nausea (43% to 61%), vomiting (18% to 26%), diarrhea (12% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Uterine cramping (83%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (10%), fever (4%), insomnia (3%), anxiety (2%), fainting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Uterine hemorrhage (5%), vaginitis (3%), pelvic pain (2%),  endometriosis/salpingitis/pelvic inflammatory disease (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Decreased hemoglobin &gt;2 g/dL (6%), anemia (2%), leukorrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (9%), rigors (3%), leg pain (2%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Adult respiratory distress syndrome (ADRS), allergic reaction including urticaria and hives, bacterial infection (including an ectopic bacteria such as",
"     <i>",
"      Clostridium sordellii",
"     </i>",
"     ), Crohn's disease (exacerbation), disseminated intravascular coagulopathy (DIC), dyspnea, hematometra, hypotension, lightheadedness, loss of consciousness, MI, pancreatitis (acute), pelvic infection, postabortal infection, QT prolongation, ruptured ectopic pregnancy, sepsis, septic shock, sickle cell crisis (exacerbation), tachycardia, toxic shock syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Unresectable meningioma trials:",
"     </b>",
"     Most common adverse effects included breast tenderness or gynecomastia, fatigue, hair thinning, hot flashes, and rash. In premenopausal women, vaginal bleeding may be seen shortly after beginning therapy and cessation of menses is common. Thyroiditis and effects related to antiglucocorticoid activity have also been noted.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mifepristone or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Korlym&trade; (additional contraindications): Concomitant use of lovastatin, simvastatin, or CYP3A substrates with a narrow therapeutic range (eg, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinine, sirolimus, tacrolimus); concomitant use of systemic corticosteroids for serious medical conditions (eg, immunosuppression following organ transplant); women with a history of unexplained vaginal bleeding, or endometrial hyperplasia with atypia or endometrial carcinoma; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mifeprex&reg; (additional contraindications): Hypersensitivity to misoprostol; chronic adrenal failure; porphyrias; hemorrhagic disorder or concurrent anticoagulant therapy; pregnancy termination &gt;49 days; intrauterine device (IUD) in place; ectopic pregnancy or undiagnosed adnexal mass; concurrent long-term corticosteroid therapy; inadequate or lack of access to emergency medical services; inability to understand effects and/or comply with treatment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: When used for the treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome, adrenal insufficiency may occur. Serum cortisol concentrations remain elevated and may increase, and cannot be used for monitoring. If signs and symptoms of adrenal insufficiency occur (eg, fatigue, hypoglycemia, hypotension, nausea, weakness), discontinue mifepristone and administer glucocorticoids (high doses may be needed). Following resolution, treatment may be resumed at a lower dose; evaluate patient for precipitating causes (eg, infection, trauma).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial infections:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     When used for the termination of pregnancy,",
"     <b>",
"      bacterial infections have been reported following use of this product and may have an atypical presentation. In rare cases, these infections may be serious and/or fatal,",
"     </b>",
"     with septic shock as a potential complication. A causal relationship has not been established. Sustained fever, abdominal pain, or pelvic tenderness should prompt evaluation; however, healthcare professionals are warned that atypical presentations of serious infection without these symptoms have also been noted. Patients presenting with nausea, vomiting, diarrhea, or weakness, with or without abdominal pain or fever, should be evaluated for serious bacterial infection when symptoms occur &gt;24 hours after taking misoprostol. Treatment with antibiotics, including coverage for anaerobic bacteria (eg,",
"     <i>",
"      Clostridium sordellii",
"     </i>",
"     ) should be initiated. Patients with Cushing&rsquo;s syndrome may be at risk for opportunistic infections such as",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Regardless of indication, endometrial proliferation is promoted by mifepristone,  resulting in endometrial thickening, cystic dilation of endometrial glands, and vaginal bleeding.",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     When used for the termination of pregnancy,",
"     <b>",
"      patients should be counseled to seek medical attention in cases of excessive bleeding. Bleeding occurs and should be expected",
"     </b>",
"     (average 9-16 days, may be &ge;30 days).",
"     <b>",
"      In some cases, bleeding may be prolonged and heavy and may be a sign of incomplete abortion or other complications,",
"     </b>",
"     potentially leading to hypovolemic shock; the manufacturer cites soaking through 2 thick sanitary pads per hour for 2 consecutive hours as an example of excessive bleeding. Bleeding may require blood transfusion (rare), curettage, saline infusions, and/or vasoconstrictors. Patients should be instructed to seek medical attention if prolonged heavy vaginal bleeding occurs. When used for termination of pregnancy, use is contraindicated in women with hemorrhagic disorders or those using anticoagulants; use caution in women with severe anemia, hypocoagulability or hemostatic disorders. When used for the treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome, use caution in women with hemorrhagic disorders or women using anticoagulants and evaluate unexplained vaginal bleeding; use is contraindicated with a history of unexplained vaginal bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: May occur at any time during therapy when used to control hyperglycemia in patients with Cushing&rsquo;s syndrome. Correct hypokalemia prior to initiation of treatment; monitor potassium levels closely with therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: May prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval (dose related); use caution with other QT-prolonging agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: When used for the termination of pregnancy, safety and efficacy have not been established for use in women with chronic cardiovascular disease as well as hypertension. Because mifepristone does not reduce serum cortisol concentrations, mineralocorticoid receptors in cardiac tissue may be activated; use caution in patients with Cushing&rsquo;s syndrome who also have heart failure or coronary vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Safety and efficacy have not been established for use in insulin-dependent diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: In patients with moderate hepatic impairment, a large variability in exposure to mifepristone and its metabolites was observed at doses of 600 mg/day. Safety and efficacy have not been established for use in women with hepatic impairment when used as a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: In patients with severe renal impairment, exposure to mifepristone and its metabolites was increased and a large variability in exposure was observed following multiple doses used in patients with Cushing&rsquo;s syndrome. Safety and efficacy have not been established for use in women with renal impairment when used as a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Safety and efficacy have not been established for use in women with respiratory disease when used as a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroids: Use of mifepristone for the treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome may antagonize the effects of steroids used for other conditions. Use is contraindicated when steroids are required for lifesaving indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for drug interactions: High potential for drug interactions exists when used for the treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome. Refer to drug interactions for detailed information.  The potential for drug interactions was not specifically studied following a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Use of mifepristone will result in termination of pregnancy.",
"     </b>",
"     When used to control hyperglycemia in women with Cushing&rsquo;s syndrome,",
"     <b>",
"      pregnancy must be excluded prior to initiation of therapy. Nonhormonal contraception must be used during treatment and for 1 month after discontinuation of therapy unless the patient has had surgical sterilization. Pregnancy must be excluded if treatment is interrupted for &ge;14 days.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Use with caution in patients who are heavy smoker (&gt;10 cigarettes/day); these patients were excluded from clinical trials when used as a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women &gt;35 years: Use with caution in women &gt;35 years of age; these patients were excluded from clinical trials when used as a single dose for the termination of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Confirmation of terminated pregnancy: When used for the termination of pregnancy, confirmation of pregnancy termination by clinical exam or ultrasound must be made 14 days following treatment. Manufacturer recommends surgical termination of pregnancy when medical termination fails or is not complete. Prescriber should determine in advance whether they will provide such care themselves or through other providers. Preventative measures to prevent rhesus immunization must be taken prior to surgical abortion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ectopic pregnancy: Ultrasound should be used if an ectopic pregnancy is suspected or if duration of pregnancy is uncertain. Ultrasonography may not identify all ectopic pregnancies, and healthcare providers should be alert for signs and symptoms which may be related to undiagnosed ectopic pregnancy in any patient who receives mifepristone. Mifepristone is not effective in terminating ectopic pregnancies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: When used for the termination of pregnancy, to be administered only by physicians who can date pregnancy, diagnose ectopic pregnancies, provide access to surgical abortion (if needed), and can provide access to emergency care. Medication will be distributed directly to these physicians following signed agreement with the distributor. Must be administered under supervision by the qualified physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication guide:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     When used for the termination of pregnancy,",
"     <b>",
"      patients undergoing treatment with mifepristone should be instructed to bring their medication guide with them when an obtaining treatment from an emergency room or healthcare provider that did not prescribe the medication initially in order to identify that they are undergoing a medical abortion.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     When used for the termination of pregnancy,",
"     <b>",
"      patient must be instructed of the treatment procedure and expected effects.",
"     </b>",
"     A signed agreement form must be kept in the patient's file. Physicians may obtain patient agreement forms, physician enrollment forms, and medical consultation directly from Danco Laboratories at 1-877-432-7596. Prescriber should also give the patient clear instructions on whom to call and what to do in the event of an emergency following administration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy dating: Pregnancy is dated from day 1 of last menstrual period (presuming a 28-day cycle, ovulation occurring midcycle). Pregnancy duration can be determined using menstrual history and clinical examination. Ultrasound should be used if duration of pregnancy is uncertain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reporting of adverse effects:  When used for the termination of pregnancy, adverse effects (including blood transfusions, hospitalization, ongoing pregnancy, and other major complications) must be reported in writing to the medication distributor.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Mifepristone may increase the serum concentration of BuPROPion.  Management: Use bupropion with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Mifepristone may diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens).  Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Mifepristone may diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).  Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Mifepristone may diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).  Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Mifepristone may increase the serum concentration of CycloSPORINE (Systemic).  Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: Mifepristone may increase the serum concentration of CYP2C8 Substrates.  Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: Mifepristone may increase the serum concentration of CYP2C9 Substrates.  Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mifepristone. Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Mifepristone may increase the serum concentration of CYP3A4 Substrates.  Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Mifepristone may increase the serum concentration of Digoxin.  Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Mifepristone may increase the serum concentration of Dihydroergotamine.  Management: Avoid dihydroergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Mifepristone may increase the serum concentration of Efavirenz.  Management: Use efavirenz with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Mifepristone may increase the serum concentration of Ergotamine.  Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Mifepristone may increase the serum concentration of FentaNYL.  Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Mifepristone may increase the serum concentration of Fluvastatin.  Management: Use fluvastatin at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Mifepristone may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Mifepristone may increase the serum concentration of Lovastatin.  Management: Avoid lovastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: Mifepristone may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Mifepristone may enhance the QTc-prolonging effect of Pimozide. Mifepristone may increase the serum concentration of Pimozide.  Management: Avoid pimozide during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): Mifepristone may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).  Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Mifepristone may enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine.  Management: Avoid quinidine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Mifepristone may increase the serum concentration of Simvastatin.  Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Mifepristone may increase the serum concentration of Sirolimus.  Management: Avoid sirolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Mifepristone may enhance the QTc-prolonging effect of Tacrolimus (Systemic). Mifepristone may increase the serum concentration of Tacrolimus (Systemic).  Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit mifepristone metabolism, leading to increased levels. Management: Do not take with grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may induce mifepristone metabolism, leading to decreased levels. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of mifepristone in a pregnant woman will result in fetal loss. In addition, skull deformities were observed in rabbit reproduction studies and were most likely due to uterine contractions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Korlym&trade;:",
"     <b>",
"      [U.S. Boxed Warning]: Use of mifepristone will result in termination of pregnancy.",
"     </b>",
"     When used to control hyperglycemia in women with Cushing&rsquo;s syndrome,",
"     <b>",
"      pregnancy must be excluded prior to initiation of therapy. Nonhormonal contraception must be used during treatment and for 1 month after discontinuation of therapy unless the patient has had surgical sterilization. Pregnancy must be excluded if treatment is interrupted for &ge;14 days.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifeprex&reg;: This medication is used to terminate pregnancy; there are no approved treatment indications for its use during pregnancy. In addition, skull defects, cranial nerve palsies, delayed growth and psychomotor development, facial malformations and limb defects have been reported following prostaglandin exposure (including misoprostol). If treatment fails, there is a risk of fetal malformation. In sexually active women, pregnancy can occur prior to the first menstrual period following treatment. Appropriate contraception can be started as soon as termination of pregnancy is confirmed or before sexual intercourse is resumed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F196808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mifepristone milk concentrations were evaluated in lactating women receiving a single dose for the termination of pregnancy. In women receiving mifepristone 200 mg (n=2), milk concentrations were below the limit of detection (&lt;0.013 micromole/L) in samples collected over the following 5 days. The highest milk concentration following a single 600 mg dose (n=10) was 0.913 micromole/L on day 1 and concentrations decreased to 0.062 micromole/L by day 5. Using the highest reported milk concentration, the authors calculated the relative infant dose to be &le;1.5% of the weight adjusted maternal dose in a fully breastfed infant (S&auml;&auml;v,  2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When using this medication for termination of pregnancy, the manufacturer recommends that breast milk be discarded for a few days following the last dose. When using for the treatment of hyperglycemia in women with Cushing&rsquo;s syndrome, the manufacturer recommends that the decision to continue or discontinue breast-feeding during therapy take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Korlym Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (28): $6854.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mifeprex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (3): $270.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome: Signs and symptoms of adrenal insufficiency (serum cortisol concentrations will not be accurate); thyroid function; serum potassium (1-2 weeks after initiating dose or dose increase, then periodically thereafter); serum glucose and psychiatric symptoms (may show response to therapy within 6 weeks); cushingoid appearance (acne, hirsutism, striae, weight may take &gt;2 months of therapy to show improvement); vaginal ultrasound in women (annually)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Termination of pregnancy: Clinical exam and/or ultrasound to confirm complete termination of pregnancy; hemoglobin, hematocrit, and red blood cell count in cases of heavy bleeding. Consider CBC in any patient who reports nausea, vomiting, or diarrhea and weakness with or without abdominal pain, and without fever or other signs of infection more than 24 hours after administration of misoprostol.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abortom (IN);",
"     </li>",
"     <li>",
"      Apano (TW);",
"     </li>",
"     <li>",
"      Mifegyn (RU);",
"     </li>",
"     <li>",
"      Mifegyne (AT, BE, CH, DE, DK, EE, FI, FR, GB, GR, IL, NL, NO, NZ, PT, SE, ZA);",
"     </li>",
"     <li>",
"      Mifolian (CL);",
"     </li>",
"     <li>",
"      Si Mi An (CL);",
"     </li>",
"     <li>",
"      Unwanted (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mifepristone is a synthetic steroid. At low doses, it competitively binds to the intracellular progesterone receptor, blocking the effects of progesterone. When used for the termination of pregnancy, this leads to contraction-inducing activity in the myometrium. In the absence of progesterone, mifepristone acts as a partial progesterone agonist. At high doses used for the treatment of hyperglycemia in patients with Cushing&rsquo;s syndrome, mifepristone blocks the effect of cortisol at the glucocorticoid receptor (antagonizes the effects of cortisol on glucose metabolism) while at the same time increasing circulating cortisol concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to three metabolites (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 69%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Single dose: Terminal: 18 hours following a slower phase where 50% eliminated between 12-72 hours; Multiple doses (600 mg/day): 85 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 90 minutes; Range: Single dose: 1-2 hours, Multiple doses: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (83%); urine (9%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG,  ACOG Practice Bulletin, Clinical Management Guidelines of Obstetrician-Gynecologists, Number 67, October 2005, \"Medical Management of Abortion,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 106(4):871-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/16199653/pubmed\" id=\"16199653\" target=\"_blank\">",
"        16199653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      FIGO Working Group on Prevention of Unsafe Abortion and its Consequences, \"The Combination of Mifepristone and Misoprostol for the Termination of Pregnancy,\"",
"      <i>",
"       Int J Gynaecol Obstet",
"      </i>",
"      , 2011, 115(1):1-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/21872858/pubmed\" id=\"21872858\" target=\"_blank\">",
"        21872858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer M, Bhatnagar J, Guarner J, et al, \"Fatal Toxic Shock Syndrome Associated With",
"      <i>",
"       Clostridium sordellii",
"      </i>",
"      After Medical Abortion,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(22):2352-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/16319384/pubmed\" id=\"16319384\" target=\"_blank\">",
"        16319384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gary MM and Harrison DJ, \"Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):191-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/16380436/pubmed\" id=\"16380436\" target=\"_blank\">",
"        16380436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grunberg SM, Weiss MH, Spitz IM, et al, &ldquo;Treatment of Unresectable Meningiomas With the Antiprogesterone Agent Mifepristone,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 1991, 74(6):861-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/2033444/pubmed\" id=\"2033444\" target=\"_blank\">",
"        2033444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johanssen S and Allolio B, \"Mifepristone (RU 486) in Cushing's Syndrome,\"",
"      <i>",
"       Eur J Endocrinol",
"      </i>",
"      , 2007, 157(5):561-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/17984235/pubmed\" id=\"17984235\" target=\"_blank\">",
"        17984235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrault D, Eisenhauer EA, Pritchard KI, et al, &ldquo;Phase II Study of the Progesterone Antagonist Mifepristone in Patients With Untreated Metastatic Breast Carcinoma: A National Cancer Institute of Canada Clinical Trials Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(10):2709-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/8874331/pubmed\" id=\"8874331\" target=\"_blank\">",
"        8874331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rocereto TF, Saul HM, Aikins JA, et al, &ldquo;Phase II Study of Mifepristone (RU486) in Refractory Ovarian Cancer,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2000, 77(3):429-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/10831354/pubmed\" id=\"10831354\" target=\"_blank\">",
"        10831354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&auml;&auml;v I, Fiala C, H&auml;m&auml;l&auml;inen JM, et al, \"Medical Abortion in Lactating Women -- Low Levels of Mifepristone in Breast Milk,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2010, 89(5):618-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/20367522/pubmed\" id=\"20367522\" target=\"_blank\">",
"        20367522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spitz IM and Bardin CW, &ldquo;Mifepristone (RU486) - A Modulator of Progestin and Glucocorticoid Action,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(6):404-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/45/1753/abstract-text/8326975/pubmed\" id=\"8326975\" target=\"_blank\">",
"        8326975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10263 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1753=[""].join("\n");
var outline_f1_45_1753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709088\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196821\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196848\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196823\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196824\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196825\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196826\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196800\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196784\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234091\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874904\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897500\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196801\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196844\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196856\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196846\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196804\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196788\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196841\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196792\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196816\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196795\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196807\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196831\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196808\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323420\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196797\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539895\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196787\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196803\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/15/2295?source=related_link\">",
"      Mifepristone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1754="Malignancies of the renal pelvis and ureter";
var content_f1_45_1754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancies of the renal pelvis and ureter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/45/1754/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/45/1754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mucosal surfaces of the renal collecting tubules, calyces, and pelvis, as well as the ureter, bladder, and urethra, all have the same embryologic origin, and the term \"urothelium\" is used to delineate the lining surface epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/1\">",
"     1",
"    </a>",
"    ]. This common embryologic origin has important implications for the management of patients with these tumors.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of malignancies arising in the urothelium of the renal pelvis or ureter are reviewed here. Urothelial tumors originating in the bladder and urethra are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"     \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=see_link\">",
"     \"Urethral cancer in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=see_link\">",
"     \"Urethral cancer in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial (also called transitional cell) carcinomas of the upper urinary tract and bladder tend to be multifocal. This phenomenon is termed \"field cancerization\" and is thought to be caused by exposure of the urothelium to potential carcinogens that are either excreted in the urine or activated by hydrolyzing enzymes in the urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=see_link\">",
"     \"Pathology of bladder neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary tumors arising in the renal pelvis include urothelial carcinomas (also called transitional cell carcinomas), squamous cell carcinomas, and adenocarcinomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 90 percent of tumors of the renal pelvis and ureter are of urothelial origin and are histologically identical to those originating in the bladder.",
"     </li>",
"     <li>",
"      Squamous cell carcinomas account for approximately 8 percent of tumors of the renal pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/2\">",
"       2",
"      </a>",
"      ]. These tumors are associated with a poorer prognosis than urothelial tumors because they tend to be sessile and deeply invasive at presentation. Squamous cell carcinomas have been associated with antecedent calculi or chronic infection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary adenocarcinoma arising in the renal pelvis is exceedingly rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drop metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial tumors can spread to urothelial structures that are either distal or proximal to the primary tumor (so called &ldquo;drop metastases&rdquo;). Upper urinary tract tumors frequently are multiple or occur synchronously with bladder tumors. This may reflect the propensity of neoplastic cells to flow down from the renal pelvis or reflux from the bladder to the ureter, forming an invasive implant.",
"   </p>",
"   <p>",
"    Drop metastases may be difficult to differentiate from separate primary lesions. Recurrent bladder tumors often cluster around the ureteral orifice of an affected ureter, thus providing evidence for their origin as metastases from the original primary tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metastatic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors from outside the genitourinary tract may spread to the renal pelvis or ureter by hematogenous or lymphatic channels, or may involve these structures by direct extension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Signs and symptoms of metastatic disease to the urinary tract usually appear late in the course of disease and may only be recognized preterminally or at autopsy.",
"   </p>",
"   <p>",
"    Direct invasion of the ureter by a nongenitourinary malignancy most commonly occurs with carcinoma of the cervix, carcinoma of the colon, or retroperitoneal lymphoma. Most compress rather than invade the ureter. Treatment is directed toward the primary tumor and relief of bilateral ureteral obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the upper urinary tract are almost twice as common in men compared with women, with a mean age at diagnosis of 73 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/7\">",
"     7",
"    </a>",
"    ]. The age-adjusted annual incidence rates of ureteral and renal pelvis cancer in the Surveillance, Epidemiology and End Results (SEER) database was 0.91 and",
"    <span class=\"nowrap\">",
"     1.15/100,000",
"    </span>",
"    person-years during period 1997 to 2005. It is estimated that tumors of the ureter and renal pelvis account for about 10 percent of all renal tumors, with approximately 3000 cases in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of upper urinary tract tumors has increased slowly increased, and there has been an associated shift toward earlier stage disease.",
"   </p>",
"   <p>",
"    Multifocality is common since the entire urothelial surface is affected by the same carcinogenic influences (the \"field cancerization\" effect), although bilateral upper tract tumors occur in less than 2 percent of cases. Areas of invasive or in situ carcinoma may present either synchronously or metachronously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098453941\">",
"    <span class=\"h3\">",
"     Relationship to urothelial bladder cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 to 50 percent of patients with urothelial carcinoma of the renal pelvis will have urothelial cancer of the bladder, which may occur either synchronously or metachronously [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the incidence of upper tract tumors in patients with primary bladder tumors is increased compared to the general population, the incidence of upper tract tumors in patients with a history of a bladder primary is much lower. In those with a history of carcinoma in situ, the cumulative incidence of upper tract tumors is 20 to 25 percent at ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Upper urinary tract cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098454466\">",
"    <span class=\"h3\">",
"     Other environmental causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other environmental factors have been associated with the preferential development of urothelial cancer of the upper urinary tract:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balkan endemic nephropathy &ndash; In the Balkan region (Bulgaria, Greece, Romania, former Yugoslavia), an indolent inflammatory process of the renal interstitium (so called \"Balkan endemic nephropathy\") is associated with the development of urothelial tumors of the renal pelvis and ureter. In that geographic region, these urothelial tumors account for almost 50 percent of all renal cancers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19878?source=see_link\">",
"       \"Balkan endemic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lynch syndrome &ndash; Patients with Lynch syndrome have abnormalities in DNA mismatch repair. These abnormalities are classically associated with colorectal and endometrial tumors. Studies have shown that these abnormalities are also associated with urothelial neoplasms, particularly of the ureter and renal pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. The lifetime risk for urologic cancer has been estimated to be about 8 percent by age 70 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arsenic exposure &ndash; Exposure to arsenic has been associated with the development of upper urinary tract cancer in Taiwan [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link&amp;anchor=H11#H11\">",
"       \"Arsenic exposure and poisoning\", section on 'Cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phenacetin use &ndash; Habitual use of analgesics that contain phenacetin has been associated with a significant increase in the incidence of urothelial tumors of the renal pelvis and ureter [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=see_link&amp;anchor=H2#H2\">",
"       \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\", section on 'Urinary tract malignancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chinese herb nephropathy &ndash; Chinese herb nephropathy can cause a progressive renal fibrosis that is frequently associated with urothelial malignancy of the renal pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"       \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria is present at diagnosis in 70 to 95 percent of patients. Obstruction of the ureter or ureteropelvic junction due to a tumor mass causes flank pain in 8 to 40 percent of cases. Other urinary tract symptoms, such as those associated with bladder irritation, and constitutional symptoms occur in less than 10 percent of cases.",
"   </p>",
"   <p>",
"    The physical examination is usually unrevealing. In rare cases, a flank mass, caused either by the tumor or associated hydronephrosis, may be palpated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic imaging procedures and ureteroscopy are the initial diagnostic tools for patients with a suspected tumor of the ureter or renal pelvis.",
"   </p>",
"   <p>",
"    Patients with urothelial carcinoma of the upper urinary tract must be carefully evaluated at presentation for multiple synchronous tumors. Because of the high incidence of multiple tumors, the entire urinary tract, including the urethra and bladder mucosa, should be visualized either radiographically or endoscopically.",
"   </p>",
"   <p>",
"    Because of the risk of metachronous urothelial tumors, posttreatment cancer surveillance is also required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiologic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a tumor of the renal pelvis or ureter is usually suspected based upon an abnormal CT, excretory urogram (intravenous pyelogram [IVP]), or retrograde pyelography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ]. CT urography has replaced IVP in most centers, offering better visualization of the urinary collecting system as well as evaluating for direct extension or nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Gadolinium enhanced magnetic resonance urography may be an alternative for assessment of the upper urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical findings on radiographic imaging are a mass in the renal pelvis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86321 \" href=\"UTD.htm?24/46/25318\">",
"     image 1",
"    </a>",
"    ). CT or MRI of the abdomen and pelvis may also detect extension of the tumor outside the collecting system, the presence of adjacent organ involvement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of distant metastases.",
"   </p>",
"   <p>",
"    On excretory urography, the most common finding is a solitary filling defect that can be observed in 50 to 75 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75824 \" href=\"UTD.htm?1/22/1377\">",
"     image 2",
"    </a>",
"    ). Tumors of the renal pelvis may also present with multiple filling defects (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56915 \" href=\"UTD.htm?2/8/2191\">",
"     image 3",
"    </a>",
"    ), ureteropelvic junction (UPJ) obstruction with hydronephrosis, infundibular stenosis, splaying of the calyces (suggesting a renal mass), or nonvisualization of the renal collecting system. Non-contrast spiral CT can identify renal pelvic or ureteral calculi, which may appear as a filling defect on the contrast study and therefore be confused with a tumor of the collecting system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ureteropyeloscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible fiberoptic ureteroscopes allow direct visualization of the entire collecting system. This procedure is generally safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In a series of 113 patients with upper tract urothelial tumors undergoing ureteroscopy, the diagnosis was confirmed in 74 percent of upper tract tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ureteropyeloscopy allows biopsy to confirm the diagnosis and may permit endourologic treatment in carefully selected patients. However, such biopsy samples obtained during ureteropyeloscopy are small and can potentially underestimate the risk of more severe disease. As an example, in a series of 56 patients initially thought to have low-grade, noninvasive tumor, 24 (43 percent) were subsequently found to have either high-grade or invasive disease in a repeat biopsy or surgical resection specimen obtained at median of 1.5 months later. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Endourologic surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Brush biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrograde brushing of the upper urinary tract was initially described in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/31\">",
"     31",
"    </a>",
"    ]. An angiographic catheter is passed into the ureter transurethrally and positioned adjacent to the suspicious lesion. A small nylon or steel bristle brush is passed inside the lumen, and material entrapped by the bristles is sent for histologic and cytologic examination. This technique allows accurate diagnosis of moderately differentiated urothelial cancer, but it may produce false negative results in patients with low-grade lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ureteroscopy and direct biopsy have largely replaced retrograde brush biopsy, brushing and cytology may be useful in evaluating patients with positive upper tract cytology who do not have visible lesions on radiography or ureteroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologic examination of urine is less reliable for upper urinary tract neoplasms than for bladder cancers. Voided specimens for urinary cytology have a poor yield for low-grade tumors, and positive findings may reflect a synchronous bladder tumor. Retrograde collections at the time of ureteroscopy that are aided by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    diuresis may yield better results.",
"   </p>",
"   <p>",
"    A pathologist with particular expertise in cytology is critical for the interpretation of such specimens. Cytologically, nuclear characteristics generally indicate the tumor grade, but a direct correlation of the cytologic grade with histologic tumor grade and invasiveness is lacking. As an example, in one series there was agreement between cytology and histologic assessment in 70 percent of patients with upper tract urothelial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urine biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a wide range of urinary biomarkers is an area of active research for patients with known or suspected urothelial neoplasms. None of these tests has sufficient diagnostic reliability to replace endoscopy or urine cytology.",
"   </p>",
"   <p>",
"    The status of these urinary tumor markers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=see_link\">",
"     \"Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T (tumor) N (node) M (metastasis) system is widely used to stage tumors of both the renal pelvis and ureters (",
"    <a class=\"graphic graphic_table graphicRef68373 \" href=\"UTD.htm?16/38/17005\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/34\">",
"     34",
"    </a>",
"    ]. Any nodal involvement or distant metastasis constitutes stage IV disease in the TNM system. The TNM stage is correlated with outcome following definitive treatment. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Urothelial cancer of the upper urinary tract may spread by direct extension, via the lymphatics, or hematogenously. Regional lymph nodes are commonly the initial site of metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine staging procedures should include a chest radiograph or CT, radionuclide bone scan if there are symptoms suggesting bone involvement or an elevated bone-derived alkaline phosphatase, and an evaluation of hepatic, renal, and hematologic function. CT or MRI imaging of the abdomen may be performed to assess for the presence of retroperitoneal lymphadenopathy, as well as other sites of disease extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALIZED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only potentially curative treatment modality for TCC of the renal pelvis or ureter. Surgery may be carried out via open, laparoscopic, endoscopic, or percutaneous approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nephroureterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephroureterectomy, using either a laparoscopic or an open approach, with excision of a cuff of normal bladder and bladder mucosa is the gold standard for most patients with urothelial tumors of the renal pelvis or ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/36\">",
"     36",
"    </a>",
"    ]. Less extensive procedures (endourologic surgery, segmental ureterectomy) may occasionally be appropriate for patients with localized, low-grade lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Endourologic surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Segmental ureterectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with tumors arising in the renal pelvis, removal of the entire ipsilateral ureter is recommended, because approximately 20 percent of patients with residual ureteral stumps will develop tumors within the stump. Similarly, total ureterectomy and nephrectomy are recommended for patients with ureteral cancers because of the high incidence of multiple ipsilateral lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors should be considered in determining the surgical approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is very little difference between kidney-conserving and kidney-sacrificing procedures in terms of operative risk. In fact, nephroureterectomy may be performed more quickly and more easily than some less extensive procedures.",
"     </li>",
"     <li>",
"      The likelihood of local recurrence, especially with tumors of higher grade, may be higher for kidney-sparing as opposed to kidney-sacrificing procedures.",
"     </li>",
"     <li>",
"      Removal of the entire ureter and kidney obviates the need for close follow-up for metachronous ipsilateral tumors or local recurrence. This is the predominant site of recurrence and is the major focus of follow-up after kidney-sparing procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of lymph node status as a prognostic parameter was studied in a multicenter series of 1130 consecutive patients who underwent nephroureterectomy for upper tract urothelial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/41\">",
"     41",
"    </a>",
"    ]. The five-year cancer-specific survival rates were significantly better in those with negative lymph nodes compared to those not undergoing a lymph node dissection or with positive lymph nodes (77 versus 69 versus 35 percent, respectively).",
"   </p>",
"   <p>",
"    However, it is not clear whether lymph node dissection improves survival in patients with urothelial cancer of the upper urinary tract or whether the identification of patients with positive lymph nodes simply identifies a poor prognosis subset [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Laparoscopic nephroureterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic and open nephroureterectomy have not been compared in randomized trials for patients with localized urothelial carcinoma of the renal pelvis and ureter.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observational data suggest that laparoscopic nephroureterectomy decreases morbidity (eg, intraoperative blood loss, hospital stay) compared to open surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In terms of cancer recurrence, the most extensive data come from a multicenter study that included 1249 patients managed with either open (n = 979) or laparoscopic (n = 270) nephroureterectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/44\">",
"       44",
"      </a>",
"      ]. The two patient populations differed substantially; patients managed laparoscopically had significantly earlier stage tumors and significantly less frequent lymph node involvement. In this nonrandomized, retrospective analysis, there was no statistically significant difference in cancer-free survival when stage of disease, location of tumor, and the presence or absence of lymphovascular invasion were considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laparoscopic nephroureterectomy does not appear to increase the risk of local recurrence or cause frequent port metastasis. In a retrospective series of 116 laparoscopic procedures, six patients developed local recurrence (5.6 percent) and one had a port metastasis (0.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Endourologic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of equipment and techniques to directly visualize the upper urinary tract has evolved into renal-sparing approaches that are appropriate for carefully selected patients. These approaches include retrograde ureteropyeloscopic resection, either alone or in combination with antegrade percutaneous techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal-sparing approaches may be particularly useful in several settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a solitary kidney, compromised renal function, bilateral lesions, or Balkan endemic nephropathy, nephron-sparing surgery is essential whenever possible. The preferred treatment is local excision of a renal pelvic lesion with or without partial nephrectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Renal function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selected lesions involving the renal pelvis and calyceal system may be considered for conservative treatment, provided they are not high-grade urothelial cancers. Ureteroscopy may be helpful to evaluate the degree of local extension prior to surgical exploration. Small biopsy specimens obtained at ureteroscopy should be interpreted with caution, since limitations in sampling may miss areas of high-grade",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      invasive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ureteropyeloscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a ureteral tumor, ureteral excision or ureterectomy with replacement by ileum may be indicated in carefully selected cases. Local excision with adequate margins and reanastomosis should be limited to patients with a localized polypoid filling defect and a low-grade, low-stage tumor. For patients with a solitary low-grade tumor in the lower third of the ureter, distal ureterectomy with regional lymphadenectomy and ureter reimplantation with a psoas hitch represents a reasonable surgical alternative. In patients with higher grade lesions, the likelihood of synchronous upper tract lesions favors nephroureterectomy. Tumors in the middle or upper third of the ureter are generally best treated by nephroureterectomy, unless cytologic and brush-biopsy specimens demonstrate a low-grade and presumably low-stage tumor. In such patients, excisional biopsy with ureteroureterostomy can be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with carcinoma in-situ may benefit from instillation of BCG (see",
"    <a class=\"local\" href=\"#H25\">",
"     'In situ disease'",
"    </a>",
"    below). However, retrospective data suggest that this approach does not prevent recurrence in patients with invasive lesions managed by an endourologic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all patients who undergo a renal-sparing procedure, frequent surveillance is required because of the high risk of recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/39,49\">",
"     39,49",
"    </a>",
"    ]. As an example, in a single-institution series, 83 patients with a normal contralateral upper tract were managed with an endoscopic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/39\">",
"     39",
"    </a>",
"    ]. At a median follow-up of 4.6 years, 46 patients developed 76 upper tract recurrences, and bladder recurrences were identified in 37 patients. Overall, 27 patients required nephroureterectomy and nine patients died of urothelial cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Retrograde ureteropyeloscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection of renal pelvis and ureteral tumors is a newer option for patients with low-grade, limited-stage tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/28,50,51\">",
"     28,50,51",
"    </a>",
"    ]. The preferred approach is to access and resect the tumor through a retrograde ureteropyeloscopy.",
"   </p>",
"   <p>",
"    Results with this approach are illustrated by a series of 90 patients with an antecedent history of urothelial carcinoma of the bladder, who were subsequently treated endoscopically for urothelial cancers of the renal pelvis or ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/50\">",
"     50",
"    </a>",
"    ]. At a median follow-up of over four years, 105 upper urinary tract recurrences were documented in 55 patients (61 percent). In addition, 38 patients experienced a total of 91 recurrences in the bladder. At last follow-up, 17 patients had died of urothelial cancer, at a median of 3.4 years after the original diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Percutaneous techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous management can be used in conjunction retrograde ureteropyeloscopy for patients with low-grade, early-stage disease, if a complete resection is not feasible from below. In this approach, a catheter is placed percutaneously into the renal pelvis, and then passed in an antegrade fashion to allow the resection to be completed.",
"   </p>",
"   <p>",
"    In one series, percutaneous resection salvaged 9 of 15 kidneys in such patients, after a median follow-up of 63 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/52\">",
"     52",
"    </a>",
"    ]. Less well-selected patients may fare less well, with ipsilateral recurrence rates as high as 41 percent in one report of 34 patients (eight multifocal, five high-grade) followed for an average of 51 months after percutaneous management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This technique should still be considered experimental because of the risk of tumor spillage into the perirenal space; rare cases of port site recurrence have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     In situ disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with isolated in situ TCC of the upper urinary tract (ie, no invasive disease and negative random biopsies of the bladder and prostatic urethra) can be managed with instillation of bacillus Calmette-Guerin (BCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. In one report of 37 patients treated for lesions in 41 kidneys, the median recurrence-free and progression-free survival durations were 21 and 34 months, respectively, at a median follow-up of 42 months. Overall, 14 of the patients died of urothelial cancer.",
"   </p>",
"   <p>",
"    This approach should be limited to patients in whom more definitive therapy is not feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical BCG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Segmental ureterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal ureterectomy with reimplantation of the ureter is the preferred procedure for low-grade distal tumors. Segmental ureterectomy may also be appropriate for carefully selected patients with compromised renal function. This approach is supported by a Surveillance, Epidemiology and End Results (SEER) database analysis that included 569 patients who underwent segmental ureterectomy and 1222 treated with nephroureterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Postoperative treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials on the role of postoperative radiation therapy (RT) in patients who have had a complete resection of an upper urinary tract cancer. Observational studies suggest that postoperative radiation may diminish the likelihood of local recurrence, but it does not appear to have an impact on overall survival or the subsequent development of distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential role for postoperative RT is illustrated by a series 67 patients who had undergone a curative resection for urothelial cancer of the upper urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/59\">",
"     59",
"    </a>",
"    ]. Local recurrence developed in 1 of 10 (10 percent) who had received postoperative RT compared with 14 of 57 (25 percent) who were managed without adjuvant RT. On multivariate analysis, tumor grade and the use of adjuvant RT had a significant impact on local control, while the development of distant metastases was solely dependent upon stage. Unresectable local disease was present in another 19 cases, 11 of which were treated RT. There were two long-term survivors among these 11 cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that evaluate adjuvant chemotherapy following complete resection of urothelial carcinoma of upper urinary tract. Although several small observational series suggested that adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy might decrease the risk of distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], the most extensive experience suggests that adjuvant chemotherapy does not have a major role [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international database study identified 1390 patients who underwent nephroureterectomy for nonmetastatic disease over a 15-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/64\">",
"     64",
"    </a>",
"    ]. Within this series, 542 cases were classified as high-risk, based upon a T3 or T4 primary tumor or the presence of lymph node involvement. Of these, 121 (22 percent) received adjuvant chemotherapy, which consisted of either the MVAC regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) or the GC regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , cisplatin) in about 80 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link&amp;anchor=H1495809154#H1495809154\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\", section on 'Cisplatin-based regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There were no statistically significant differences in overall survival or cancer-specific survival compared to high-risk patients not given adjuvant chemotherapy (hazard ratio 1.06 [95% CI 0.80-1.40] and 1.26 [95% CI 0.93-1.71], respectively). A possible explanation for the trend toward worse outcomes in patients given adjuvant chemotherapy is that such therapy might have been preferentially given to patients with higher stage and grade disease.",
"   </p>",
"   <p>",
"    At least one observational series suggests that chemotherapy with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimen may also have a role in combination with radiation therapy in patients who have undergone a resection for urothelial upper urinary tract malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indirect evidence regarding the role of adjuvant chemotherapy for patients with urothelial malignancies of the upper urinary tract may eventually come from ongoing randomized trials in patients with resected urothelial bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link&amp;anchor=H1072936968#H1072936968\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\", section on 'Contemporary trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemotherapy has an important role in the management of patients with locally advanced urothelial cancer of the bladder. However, there are only very limited data on the role of this approach in urothelial carcinoma of the upper urinary tract, and prospective studies are needed to assess the role of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An observational study in 43 patients suggested that this approach resulted in significant down-staging compared to patients treated with immediate surgery; six of 43 patients (14 percent) had a complete response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/66\">",
"     66",
"    </a>",
"    ]. In another retrospective study, 18 patients with histologically positive lymph nodes were treated with primary chemotherapy followed by surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/67\">",
"     67",
"    </a>",
"    ]. The five-year cancer specific survival in this subset was 44 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with urothelial carcinoma of the upper urinary tract are at high risk for the subsequent development of urothelial tumors of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. This was illustrated by a series of 82 patients who had complete resection of a TCC of the renal pelvis or ureter, in which urothelial carcinoma was subsequently diagnosed in 36 (44 percent) at a median interval of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/72\">",
"     72",
"    </a>",
"    ]. The bladder tumors were frequently multifocal (mean 2.1 per patient).",
"   </p>",
"   <p>",
"    For patients who have undergone a nephroureterectomy, we monitor with cystoscopy every six months for several years and then annually thereafter, based upon our approach in those who have been treated for a non-muscle invasive bladder cancer. For patients who have undergone a renal-sparing procedure, surveillance should be extended to include the upper tract because of the risk of recurrence in the renal pelvis or ureter. This may include upper tract imaging (CT or magnet resonance urography)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ureteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TREATMENT OF ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the efficacy of chemotherapy specifically in patients with advanced upper urinary tract urothelial cancers. Treatment is based upon the much larger experience in patients with advanced urothelial bladder cancer.",
"   </p>",
"   <p>",
"    Patients with advanced urothelial cancer have often been included in trials for patients with metastatic urothelial bladder cancer. In those trials, urothelial cancers have been responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and cisplatin (MVAC, (",
"    <a class=\"graphic graphic_table graphicRef64950 \" href=\"UTD.htm?28/7/28798\">",
"     table 2",
"    </a>",
"    )) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus cisplatin (GC, (",
"    <a class=\"graphic graphic_table graphicRef53016 \" href=\"UTD.htm?13/5/13406\">",
"     table 3",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic kidney disease is common in patients with urothelial cancer of the upper urinary tract, and this can make the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy regimens difficult or impossible [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis following definitive treatment for urothelial tumors of the upper urinary tract is related to the stage of the primary tumor and the presence or absence of regional lymph node involvement, as well as tumor grade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Staging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The importance of stage was illustrated by a series of 1363 patients with urothelial cancer of the upper urinary tract treated with curative intent at 12 centers between 1992 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/76\">",
"     76",
"    </a>",
"    ]. Nephroureterectomy was performed with open and laparoscopic approaches in 77 and 23 percent of cases, and lymphadenectomy was performed in 43 percent. Median follow-up was 37 months.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the entire cohort, the five-year cancer-specific survival was 73 percent.",
"     </li>",
"     <li>",
"      The prognosis worsened with increasing stage of the primary tumor. The five-year cancer-specific survival rates for patients with",
"      <span class=\"nowrap\">",
"       pT0/Ta/Tis,",
"      </span>",
"      pT1, pT2, pT3, and pT4 were 94, 91, 75, 54, and 12 percent, respectively (",
"      <a class=\"graphic graphic_table graphicRef68373 \" href=\"UTD.htm?16/38/17005\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with low-grade tumors had a significantly better prognosis than those with high-grade tumors (five-year cancer-specific survival 89 versus 63 percent).",
"     </li>",
"     <li>",
"      Patients with negative nodes or who did not undergo lymphadenectomy had a better prognosis than those with positive lymph nodes (five-year cancer-specific survival 77 versus 35 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no major difference in prognosis between urothelial carcinomas arising the ureter compared with those originating in the renal pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/45/1754/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with transitional cell carcinoma (TCC) of the upper urinary tract (renal pelvis, ureter) and without evidence of metastatic or unresectable locally advanced disease, we recommend surgical resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of localized disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, nephroureterectomy with excision of a cuff of normal bladder and bladder mucosa is the preferred procedure. For patients with a low-grade (T1-T2) lesion of the distal ureter, a segmental resection with reimplantation of the ureter is preferred (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of localized disease'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The frequent occurrence of synchronous or metachronous multifocal tumors makes a less extensive resection contraindicated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nephroureterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open and laparoscopic surgical approaches appear to be equally safe and effective, assuming adequate expertise is available. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Laparoscopic nephroureterectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For carefully selected patients, we suggest endourologic, renal-sparing surgery rather than nephroureterectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Endourologic surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients in whom this approach is particularly appropriate include those with a solitary kidney, compromised renal function, bilateral lesions, or Balkan endemic nephropathy. Those with low-grade, low-stage tumors of the ureter or renal pelvis may also be candidates for this approach. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options in these settings include retrograde ureteropyeloscopy alone or in conjunction with an antegrade percutaneous resection. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Endourologic surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence to support the routine use of postoperative radiation therapy or adjuvant chemotherapy. Postoperative RT may be considered for patients with adverse factors, such as high grade or stage, close surgical margins, or positive nodes, in order to improve the rate of local control. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Postoperative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced disease requiring systemic treatment, the chemotherapy regimens are based upon regimens used for urothelial tumors in bladder cancer patients (MVAC [(",
"      <a class=\"graphic graphic_table graphicRef64950 \" href=\"UTD.htm?28/7/28798\">",
"       table 2",
"      </a>",
"      )] and GC [(",
"      <a class=\"graphic graphic_table graphicRef53016 \" href=\"UTD.htm?13/5/13406\">",
"       table 3",
"      </a>",
"      )]). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"       \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/1\">",
"      Melicow MM. Tumors of urinary drainage tract: urothelial tumors. J Urol 1945; 54:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/2\">",
"      Holm&auml;ng S, Lele SM, Johansson SL. Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol 2007; 178:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/3\">",
"      Paonessa J, Beck H, Cook S. Squamous cell carcinoma of the renal pelvis associated with kidney stones: a case report. Med Oncol 2011; 28 Suppl 1:S392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/4\">",
"      PRESMAN D, EHRLICH L. Metastatic tumors of the ureter. J Urol 1948; 59:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/5\">",
"      Abeloff MD, Lenhard RE Jr. Clinical management of ureteral obstruction secondary to malignant lymphoma. Johns Hopkins Med J 1974; 134:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/6\">",
"      Cohen WM, Freed SZ, Hasson J. Metastatic cancer to the ureter: a review of the literature and case presentations. J Urol 1974; 112:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/7\">",
"      Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int 2011; 107:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/8\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/9\">",
"      Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 2004; 28:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/10\">",
"      Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996; 156:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/11\">",
"      Lynch HT, Ens JA, Lynch JF. The Lynch syndrome II and urological malignancies. J Urol 1990; 143:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/12\">",
"      Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/13\">",
"      Gylling AH, Nieminen TT, Abdel-Rahman WM, et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/14\">",
"      Yang MH, Chen KK, Yen CC, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002; 59:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/15\">",
"      Lee YL, Shih MC, Wu WJ, et al. Clinical and urographic presentation of transitional cell carcinoma of the ureter in a blackfoot disease endemic area in southern Taiwan. Kaohsiung J Med Sci 2002; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/16\">",
"      Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/17\">",
"      Holm&auml;ng S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer 2004; 101:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/18\">",
"      Pommer W, Bronder E, Klimpel A, et al. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999; 14:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/19\">",
"      Gago-Dominguez M, Yuan JM, Castelao JE, et al. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/20\">",
"      Linet MS, Chow WH, McLaughlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 1995; 62:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/21\">",
"      Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/22\">",
"      Wu MJ, Lian JD, Yang CR, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004; 43:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/23\">",
"      Williams CB, Mitchell JP. Carcinoma of the ureter--a review of 54 cases. Br J Urol 1973; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/24\">",
"      Batata MA, Whitmore WF, Hilaris BS, et al. Primary carcinoma of the ureter: a prognostic study. Cancer 1975; 35:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/25\">",
"      Wang LJ, Wong YC, Huang CC, et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol 2010; 183:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/26\">",
"      Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. AJR Am J Roentgenol 2009; 192:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/27\">",
"      Takahashi N, Glockner JF, Hartman RP, et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol 2010; 183:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/28\">",
"      Blute ML, Segura JW, Patterson DE, et al. Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol 1989; 141:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/29\">",
"      Bagley DH, Rivas D. Upper urinary tract filling defects: flexible ureteroscopic diagnosis. J Urol 1990; 143:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/30\">",
"      Chitale S, Mbakada R, Irving S, Burgess N. Nephroureterectomy for transitional cell carcinoma - the value of pre-operative histology. Ann R Coll Surg Engl 2008; 90:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/31\">",
"      Gill WB, Lu CT, Thomsen S. Retrograde brushing: a new technique for obtaining histologic and cytologic material from ureteral, renal pelvic and renal caliceal lesions. J Urol 1973; 109:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/32\">",
"      Blute RD Jr, Gittes RR, Gittes RF. Renal brush biopsy: survey of indications, techniques and results. J Urol 1981; 126:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/33\">",
"      Williams SK, Denton KJ, Minervini A, et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol 2008; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     Renal pelvis and ureter. In: American Joint Committee on Cancer Staging Manualg, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/35\">",
"      Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 2008; 53:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/36\">",
"      Lughezzani G, Sun M, Perrotte P, et al. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. Eur Urol 2010; 57:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/37\">",
"      Box GN, Lehman DS, Landman J, Clayman RV. Minimally invasive management of upper tract malignancies: renal cell and transitional cell carcinoma. Urol Clin North Am 2008; 35:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/38\">",
"      Lucas SM, Svatek RS, Olgin G, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 2008; 102:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/39\">",
"      Thompson RH, Krambeck AE, Lohse CM, et al. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology 2008; 71:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/40\">",
"      Strong DW, Pearse HD. Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract. Cancer 1976; 38:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/41\">",
"      Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009; 181:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/42\">",
"      Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/43\">",
"      Gill IS, Sung GT, Hobart MG, et al. Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: the Cleveland Clinic experience. J Urol 2000; 164:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/44\">",
"      Capitanio U, Shariat SF, Isbarn H, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/45\">",
"      Muntener M, Schaeffer EM, Romero FR, et al. Incidence of local recurrence and port site metastasis after laparoscopic radical nephroureterectomy. Urology 2007; 70:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/46\">",
"      Goel MC, Matin SF, Derweesh I, et al. Partial nephrectomy for renal urothelial tumors: clinical update. Urology 2006; 67:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/47\">",
"      Smith AK, Stephenson AJ, Lane BR, et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011; 78:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/48\">",
"      Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Gu&eacute;rin therapy? Urology 2009; 73:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/49\">",
"      Krambeck AE, Thompson RH, Lohse CM, et al. Imperative indications for conservative management of upper tract transitional cell carcinoma. J Urol 2007; 178:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/50\">",
"      Krambeck AE, Thompson RH, Lohse CM, et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol 2007; 177:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/51\">",
"      Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer 2003; 98:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/52\">",
"      Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol 2003; 169:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/53\">",
"      Palou J, Piovesan LF, Huguet J, et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol 2004; 172:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/54\">",
"      Tsivian A, Sidi AA. Port site metastases in urological laparoscopic surgery. J Urol 2003; 169:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/55\">",
"      Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Gu&eacute;rin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 2000; 38:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/56\">",
"      Irie A, Iwamura M, Kadowaki K, et al. Intravesical instillation of bacille Calmette-Gu&eacute;rin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 2002; 59:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/57\">",
"      Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002; 168:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/58\">",
"      Jeldres C, Lughezzani G, Sun M, et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010; 183:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/59\">",
"      Cozad SC, Smalley SR, Austenfeld M, et al. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology 1995; 46:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/60\">",
"      Cozad SC, Smalley SR, Austenfeld M, et al. Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys 1992; 24:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/61\">",
"      Michael M, Tannock IF, Czaykowski PM, Moore MJ. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol 1998; 82:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/62\">",
"      Bamias A, Deliveliotis Ch, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/63\">",
"      Kwak C, Lee SE, Jeong IG, Ku JH. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006; 68:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/64\">",
"      Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009; 182:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/65\">",
"      Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004; 172:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/66\">",
"      Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/67\">",
"      Youssef RF, Shariat SF, Lotan Y, et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2011; 108:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/68\">",
"      Raman JD, Sosa RE, Vaughan ED Jr, Scherr DS. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007; 69:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/69\">",
"      Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/70\">",
"      Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/71\">",
"      Wu WJ, Ke HL, Yang YH, et al. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol 2010; 183:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/72\">",
"      Lang EK. The arteriographic diagnosis of primary and secondary tumors of the ureter or ureter and renal pelvis. Radiology 1969; 93:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/73\">",
"      Ku JH, Choi WS, Kwak C, Kim HH. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol 2011; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/75\">",
"      Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010; 116:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/76\">",
"      Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/77\">",
"      Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 2009; 45:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/78\">",
"      Jeldres C, Sun M, Lughezzani G, et al. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 2010; 116:3774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/79\">",
"      Cornu JN, Roupr&ecirc;t M, Carpentier X, et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/45/1754/abstract/80\">",
"      Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010; 57:1072.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2987 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1754=[""].join("\n");
var outline_f1_45_1754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drop metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metastatic tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1098453941\">",
"      - Relationship to urothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1098454466\">",
"      - Other environmental causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiologic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ureteropyeloscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Brush biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urine biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nephroureterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Laparoscopic nephroureterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Endourologic surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Retrograde ureteropyeloscopic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Percutaneous techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - In situ disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Segmental ureterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Postoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TREATMENT OF ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2987|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/46/25318\" title=\"diagnostic image 1\">",
"      CT pyelograms ureter and renal pelvis tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/22/1377\" title=\"diagnostic image 2\">",
"      IVP distal ureteral tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/8/2191\" title=\"diagnostic image 3\">",
"      IVP renal pelvic tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/38/17005\" title=\"table 1\">",
"      TNM staging renal pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/7/28798\" title=\"table 2\">",
"      MVAC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13406\" title=\"table 3\">",
"      Gemcitabine and cisplatin for metastatic urothelial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19878?source=related_link\">",
"      Balkan endemic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=related_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=related_link\">",
"      Urethral cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=related_link\">",
"      Urethral cancer in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=related_link\">",
"      Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_45_1755="Congenital myasthenic syndromes";
var content_f1_45_1755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Congenital myasthenic syndromes presenting during the neonatal period",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Decreased acetylcholine resynthesis or packaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital endplate acetylcholinesterase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetylcholine receptor deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal interaction of acetylcholine with acetylcholine receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambert-Eaton type myasthenic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paucity of secondary synaptic clefts",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1755=[""].join("\n");
var outline_f1_45_1755=null;
var title_f1_45_1756="Fetal hemoglobin by GA";
var content_f1_45_1756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemoglobin, g/dL",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GA",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        9.7",
"       </td>",
"       <td>",
"        11.3",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        13.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        10.3",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        13.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        11.3",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"       <td>",
"        13.1",
"       </td>",
"       <td>",
"        14.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        15.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        15.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"       <td>",
"        16.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1756=[""].join("\n");
var outline_f1_45_1756=null;
var title_f1_45_1757="TNM staging HCC";
var content_f1_45_1757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging for hepatocellular cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Solitary tumor without vascular invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Solitary tumor with vascular invasion or multiple tumors none more than 5 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3a",
"      </td>",
"      <td colspan=\"3\">",
"       Multiple tumors more than 5 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3b",
"      </td>",
"      <td colspan=\"3\">",
"       Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Fibrosis score (F)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       F0",
"      </td>",
"      <td colspan=\"3\">",
"       Fibrosis score 0-4 (none to moderate fibrosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       F1",
"      </td>",
"      <td colspan=\"3\">",
"       Fibrosis score 5-6 (severe fibrosis or cirrhosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T3a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       T3b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIC",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVA",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * The fibrosis score as defined by Ishak is recommended because of its prognostic value in overall survival. This scoring system uses a 0-6 scale.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1757=[""].join("\n");
var outline_f1_45_1757=null;
var title_f1_45_1758="TNM staging thyroid cancer";
var content_f1_45_1758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for thyroid cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor 2 cm or less in greatest dimension limited to the thyroid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor 1 cm or less, limited to the thyroid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor more than 1 cm but not more than 2 cm in greatest dimension, limited to the thyroid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 2 cm but not more than 4 cm in greatest dimension limited to the thyroid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm in greatest dimension limited to the thyroid or any tumor with minimal extrathyroid extension (eg, extension to sternothyroid muscle or perithyroid soft tissues)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       All anaplastic carcinomas are considered T4 tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Intrathyroidal anaplastic carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Anaplastic carcinoma with gross extrathyroid extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis to unilateral, bilateral, or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups &Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Papillary or follicular (differentiated)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Under 45 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage I",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage II",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       45 years and older",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * All categories may be subdivided: (s) solitary tumor and (m) multifocal tumor (the largest determines the classification).",
"     <br>",
"      &bull; Regional lymph nodes are the central compartment, lateral cervical, and upper mediastinal lymph nodes.",
"      <br>",
"       &Delta; Separate stage groupings are recommended for papillary or follicular (differentiated), medullary, and anaplastic (undifferentiated) carcinoma.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1758=[""].join("\n");
var outline_f1_45_1758=null;
var title_f1_45_1759="Partial bicornuate uterus";
var content_f1_45_1759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus bicornuate: partial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_45_1759=[""].join("\n");
var outline_f1_45_1759=null;
